<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">51480</article-id><article-id pub-id-type="doi">10.7554/eLife.51480</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-155277"><name><surname>Baslan</surname><given-names>Timour</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5674-6432</contrib-id><email>baslant@mskcc.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-77583"><name><surname>Kendall</surname><given-names>Jude</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157022"><name><surname>Volyanskyy</surname><given-names>Konstantin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157023"><name><surname>McNamara</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-77581"><name><surname>Cox</surname><given-names>Hilary</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157024"><name><surname>D'Italia</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157025"><name><surname>Ambrosio</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157026"><name><surname>Riggs</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157027"><name><surname>Rodgers</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157028"><name><surname>Leotta</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157029"><name><surname>Song</surname><given-names>Junyan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157030"><name><surname>Mao</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157031"><name><surname>Wu</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-157032"><name><surname>Shah</surname><given-names>Ronak</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157033"><name><surname>Gularte-Mérida</surname><given-names>Rodrigo</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157034"><name><surname>Chadalavada</surname><given-names>Kalyani</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157035"><name><surname>Nanjangud</surname><given-names>Gouri</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-51224"><name><surname>Varadan</surname><given-names>Vinay</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1520-1967</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157036"><name><surname>Gordon</surname><given-names>Assaf</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-157037"><name><surname>Curtis</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157038"><name><surname>Krasnitz</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157039"><name><surname>Dimitrova</surname><given-names>Nevenka</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-157040"><name><surname>Harris</surname><given-names>Lyndsay</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa2">‡</xref></contrib><contrib contrib-type="author" id="author-157041"><name><surname>Wigler</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-77586"><name><surname>Hicks</surname><given-names>James</given-names></name><email>jameshic@usc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa3">§</xref></contrib><aff id="aff1"><label>1</label><institution>Cold Spring Harbor Laboratory</institution><addr-line><named-content content-type="city">Cold Spring Harbor</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Molecular and Cellular Biology, Stony Brook University</institution><addr-line><named-content content-type="city">Stony Brook</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Philips Research North America, Biomedical Informatics</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Genetics, Stanford University School of Medicine</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Applied Mathematics and Statistics, Stony Brook University</institution><addr-line><named-content content-type="city">Stony Brook</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Surgery, Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Case Comprehensive Cancer Center, Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>House Gordon Software Company LTD</institution><addr-line><named-content content-type="city">Calgary</named-content></addr-line><country>Canada</country></aff><aff id="aff11"><label>11</label><institution>Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University School of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Seidman Cancer Center, University Hospitals of Case Western</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Valencia</surname><given-names>Alfonso</given-names></name><role>Reviewing Editor</role><aff><institution>Barcelona Supercomputing Center - BSC</institution><country>Spain</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Settleman</surname><given-names>Jeffrey</given-names></name><role>Senior Editor</role><aff><institution>Pfizer</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, United States</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>National Institutes of Health, Bethesda, United States</p></fn><fn fn-type="present-address" id="pa3"><label>§</label><p>USC Dana and David Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, United States</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>05</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e51480</elocation-id><history><date date-type="received" iso-8601-date="2019-08-30"><day>30</day><month>08</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-04-03"><day>03</day><month>04</month><year>2020</year></date></history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-51480-v1.pdf"/><abstract><p>Copy number alterations (CNAs) play an important role in molding the genomes of breast cancers and have been shown to be clinically useful for prognostic and therapeutic purposes. However, our knowledge of intra-tumoral genetic heterogeneity of this important class of somatic alterations is limited. Here, using single-cell sequencing, we comprehensively map out the facets of copy number alteration heterogeneity in a cohort of breast cancer tumors. Ou/var/www/html/elife/12-05-2020/backup/r analyses reveal: genetic heterogeneity of non-tumor cells (i.e. stroma) within the tumor mass; the extent to which copy number heterogeneity impacts breast cancer genomes and the importance of both the genomic location and dosage of sub-clonal events; the pervasive nature of genetic heterogeneity of chromosomal amplifications; and the association of copy number heterogeneity with clinical and biological parameters such as polyploidy and estrogen receptor negative status. Our data highlight the power of single-cell genomics in dissecting, in its many forms, intra-tumoral genetic heterogeneity of CNAs, the magnitude with which CNA heterogeneity affects the genomes of breast cancers, and the potential importance of CNA heterogeneity in phenomena such as therapeutic resistance and disease relapse.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Cells in the body remain healthy by tightly preventing and repairing random changes, or mutations, in their genetic material. In cancer cells, however, these mechanisms can break down. When these cells grow and multiply, they can then go on to accumulate many mutations. As a result, cancer cells in the same tumor can each contain a unique combination of genetic changes.</p><p>This genetic heterogeneity has the potential to affect how cancer responds to treatment, and is increasingly becoming appreciated clinically. For example, if a drug only works against cancer cells carrying a specific mutation, any cells lacking this genetic change will keep growing and cause a relapse. However, it is still difficult to quantify and understand genetic heterogeneity in cancer.</p><p>Copy number alterations (or CNAs) are a class of mutation where large and small sections of genetic material are gained or lost. This can result in cells that have an abnormal number of copies of the genes in these sections. Here, Baslan et al. set out to explore how CNAs might vary between individual cancer cells within the same tumor.</p><p>To do so, thousands of individual cancer cells were isolated from human breast tumors, and a technique called single-cell genome sequencing used to screen the genetic information of each of them. These experiments confirmed that CNAs did differ – sometimes dramatically – between patients and among cells taken from the same tumor. For example, many of the cells carried extra copies of well-known cancer genes important for treatment, but the exact number of copies varied between cells. This heterogeneity existed for individual genes as well as larger stretches of DNA: this was the case, for instance, for an entire section of chromosome 8, a region often affected in breast and other tumors.</p><p>The work by Baslan et al. captures the sheer extent of genetic heterogeneity in cancer and in doing so, highlights the power of single-cell genome sequencing. In the future, a finer understanding of the genetic changes present at the level of an individual cancer cell may help clinicians to manage the disease more effectively.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer</kwd><kwd>genomics</kwd><kwd>single-cell sequencing</kwd><kwd>copy number alterations</kwd><kwd>genetics</kwd><kwd>breast cancer</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-11-10747</award-id><principal-award-recipient><name><surname>Wigler</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001006</institution-id><institution>Breast Cancer Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hicks</surname><given-names>James</given-names></name><name><surname>Wigler</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Philips Research North America</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hicks</surname><given-names>James</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>NIH</institution></institution-wrap></funding-source><award-id>P30 -CA008748</award-id><principal-award-recipient><name><surname>Nanjangud</surname><given-names>Gouri</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>William C and Joyce C O'Neil Charitable Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Baslan</surname><given-names>Timour</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>McFarland Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wigler</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>Research professor</award-id><principal-award-recipient><name><surname>Wigler</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009634</institution-id><institution>Susan G. Komen</institution></institution-wrap></funding-source><award-id>IIR13265578</award-id><principal-award-recipient><name><surname>Hicks</surname><given-names>James</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007052</institution-id><institution>Memorial Sloan-Kettering Cancer Center</institution></institution-wrap></funding-source><award-id>Single Cell Sequencing Initiative</award-id><principal-award-recipient><name><surname>Baslan</surname><given-names>Timour</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Copy number alteration heterogeneity exists in many shapes and forms in breast cancer genomes and single-cell genomics is a powerful tool to further our understanding of its nature and significance.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Research into the genetics of breast tumors has yielded comprehensive portraits of the somatic alterations acquired during the evolution of breast cancer genomes. Catalogues of recurrent driver alterations have been identified using an array of technologies (<xref ref-type="bibr" rid="bib53">Teixeira et al., 2002</xref>; <xref ref-type="bibr" rid="bib1">Adeyinka et al., 2003</xref>; <xref ref-type="bibr" rid="bib16">Chin et al., 2006</xref>; <xref ref-type="bibr" rid="bib52">Sjöblom et al., 2006</xref>; <xref ref-type="bibr" rid="bib27">Fridlyand et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Banerji et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib50">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">Ciriello et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Nik-Zainal et al., 2016</xref>). This information has been instrumental in furthering our understanding of the basic biology that underlies breast cancer development and has led to the development of diagnostic and prognostic tests and more importantly, the development of efficacious targeted therapies (<xref ref-type="bibr" rid="bib20">Dawson et al., 2013</xref>). While the adoption of therapeutic strategies targeting somatic cancer alterations and the pathways they control has had a profound impact on the treatment of breast cancer (<xref ref-type="bibr" rid="bib3">Alvarez et al., 2010</xref>), disease relapse and therapeutic resistance remain important challenges (<xref ref-type="bibr" rid="bib34">Ma et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Majewski et al., 2015</xref>). Recent research into these phenomena has implicated genetic heterogeneity (i.e. sub-clonal variation or intra-tumoral heterogeneity) as a common mechanism to explain recurrence and treatment failure (<xref ref-type="bibr" rid="bib54">Toy et al., 2013</xref>; <xref ref-type="bibr" rid="bib15">Carey et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Miller et al., 2016</xref>). However our knowledge of intra-tumoral genetic heterogeneity is limited and thus advancing it is instrumental in combating cancer.</p><p>CNAs are an important class of somatic mutations that are acquired during the evolution of breast cancer genomes (<xref ref-type="bibr" rid="bib20">Dawson et al., 2013</xref>). Studies exploring the landscape of CNAs have considerably advanced our knowledge of breast cancer biology, with translational efforts leading to advances in the clinic. Most notably, the amplification of the ERBB2 (HER2) oncogene defines a biological subtype of breast cancers and targeting this CNA has led to the development of a multitude of efficacious therapeutic agents that have dramatically increased the survival of HER2+ patients (<xref ref-type="bibr" rid="bib4">Arteaga and Engelman, 2014</xref>). Additionally, numerous studies have demonstrated the utility of copy number information in the prognostic stratification of breast tumors (<xref ref-type="bibr" rid="bib49">Russnes et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Curtis et al., 2012</xref>) and studies of the genes targeted by this class of somatic mutations have substantially advanced our understanding of breast cancer biology (<xref ref-type="bibr" rid="bib29">Gatza et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Cai et al., 2016</xref>). However, our knowledge of CNA intra-tumoral genetic heterogeneity is limited and given the importance of this class of somatic alterations warrants further investigation.</p><p>Single-cell DNA sequencing methods have recently emerged as powerful tools for the study of intra-tumoral heterogeneity with recent applications in breast (<xref ref-type="bibr" rid="bib41">Navin et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Eirew et al., 2015</xref>) and other tumors (<xref ref-type="bibr" rid="bib26">Francis et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Bolhaqueiro et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Bian et al., 2018</xref>) revealing novel cancer genetics and biology. Here, we present a comprehensive analysis of CNAs in breast cancer based on the sequencing of thousands of single-cell genomes across a cohort of breast tumors. Our results offer in-depth views of the magnitude of intra-tumoral CNA heterogeneity present in breast cancer genomes, reveal novel and important observations that have been missed by earlier bulk studies, highlight the unique nature of the data and its ability to retrieve novel knowledge, and provide an important foundation for the future exploration of intra-tumoral genetic heterogeneity of this important class of somatic mutations.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Samples, annotations and sequencing</title><p>Samples from sixteen patients were selected from a cohort population enrolled in two phase II open-label clinical trials conducted by the Brown University Oncology Group (BrUOG). Two pre-treatment, freshly frozen biopsies per patient were obtained. Two blood samples from normal healthy individuals were also obtained and processed (discussed below – Methods). For the tumor samples, one biopsy was subject to bulk DNA and RNA isolation for transcriptome sequencing and copy number profiling by sparse sequencing. The second biopsy was subjected to single-cell copy number analysis as described previously (<xref ref-type="bibr" rid="bib6">Baslan et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Baslan et al., 2015</xref>). In brief, tissue was processed to obtain a suspension of DAPI stained single-nuclei. Nuclei were subsequently flow sorted by ploidy (measured by DNA-content) for single-nucleus deposition, genome amplification and sequencing. For samples with multi-modal ploidy distributions (i.e. diploid and polyploid populations) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), single-nuclei were sorted and sequenced from each distribution. A mean of 116 single-nuclei per tumor sample were sequenced in multiplex fashion for a total of 2086 single-cell genomes. For each nucleus, we targeted a sequencing depth of roughly 2 million reads, sufficient to call large copy number events (&gt;1 MB) as well as focal events such as amplifications and deletions at a resolution of roughly 300kbs . Selected patient samples were representative of various biological and clinical variables such as PAM50 subtype, ploidy, and ER/PR/HER2 status as well as other parameters such as age and tumor size (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–D</xref>).</p></sec><sec id="s2-2"><title>CNAs and genetic heterogeneity of stromal, non-cancer cells</title><p>Nuclei processed from the diploid (2N) distribution of sorted samples could either represent cancer cells or normal cells present in the tumor mass (i.e. normal epithelia, fibroblasts, and/or immune cells). When sequencing 2N nuclei of patient samples, we obtain copy number neutral, ‘flat’ genome profiles representative of non-cancer, stromal cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Intriguingly, we observed recurrent focal homozygous deletions on chromosomes 14 and 7, in otherwise diploid genomes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Further inspection localized the deletions to T-cell receptor alpha (TCRa) and beta (TCRb) loci (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). These deletions are the result of T-cell maturation and generated via the process of V-D-J recombination. Similarly, we observed focal homozygous deletions at the heavy and light Immunoglobulin loci (IGH and IGL) on chromosomes 14 and 22, respectively, denoting B-cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Thus, using single-nuclei copy number sequencing we can detect T- and B-cells present within the tumor mass. To gauge the sensitivity of T- and B-cell detection, we retrieved highly purified CD4+/CD8+ T-cells and CD27+/CD13+ B-cells and performed single-nuclei copy number analysis on approximately 96 nuclei for both samples with the expectation that all single-nuclei should carry their respective deletions. Deletion analysis led to a calculated detection sensitivity of ~80% and 50% for T- and B-cells, respectively (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). This allowed the quantification of T- and B-cells in the tumor mass in our samples and led to the detection of T-cells (in varying proportions) in almost all patient samples, with B-cell infiltration limited to a subset of tumors, (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) consistent with previous studies (<xref ref-type="bibr" rid="bib48">Ruffell et al., 2012</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Genetic heterogeneity of immune cells and pseudo-diploid cells in breast cancer biopsies.</title><p>(<bold>A</bold>) Genome-wide copy number view of representative single-cell T-cell genomes illustrating T-Cell Receptor alpha (TCRa) and beta (TCRb) deletions. (<bold>B</bold>) Genome-wide copy number view of representative single-cell B-cell genomes illustrating light (IGL) and heavy (IGH) immunoglobulin deletions. (<bold>C</bold>) Bar plot quantification of T-cells, B-cells, pseudo-diploid cells and other non-tumor cells identified in profiled tumor biopsies. (<bold>D</bold>) Zoomed in views of TCRa deletion breakpoints in single T-cells found in tumors biopsies (P15 and P9), blood purified CD8+/4+ T-cells, and single-leukemic cells derived from a T-cell leukemia. (<bold>E</bold>) Representative genome-wide copy number plot of a T-cell exhibiting X-chromosome loss. Insert – bar plot quantification of X-loss T-cells in ER+ and ER- tumors. Asterisk denotes statistical significance based on chi-square test (p-value=0.0047). (<bold>F</bold>) Left panel: Frequency plot of CNAs identified in a panel of 200 breast cancer genomes. Highly recurrent alterations, such as 1q gain and 16 p loss are noted. Right Panel: Representative copy number plots of pseudo-diploid single-cell genomes illustrating the occurrence of recurrent breast cancer CNAs in these cells.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Patient sample associated metadata.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-51480-fig1-data1-v1.xlsx.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Characteristics of tumor samples profiled in the study.</title><p>(<bold>A</bold>) Schematic illustration of single-nuclei sorting strategy employed in the study. (<bold>B</bold>) Hierarchal clustering heatmap of breast cancer samples illustrating PAM50 subtype information based on differential gene expression analysis. Tumors analyzed in the present study (n = 16) are annotated. (<bold>C</bold>) Flow cytometric profiles of analyzed tumors illustrating ploidy distributions as measured by DNA content using DAPI staining. Asterisk denotes distribution/ploidy peak where cancer cells were detected in the single-nuclei sequencing data. (<bold>D</bold>) Illustration of summary statistics: approximate ploidy, tumor cellularity (% cancer), tumor size, and patient age of analyzed tumor samples. Ploidy and cellularity statistics are based on flow cytometry and single-nuclei sequencing data.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Single-cell sequencing analysis of T-cells retrieved from purified lymphocytes and T-cells identified in breast cancer tissue biopsies.</title><p>(<bold>A</bold>) Representative genome-wide copy number profiles of normal cells showing non-rearranged ‘flat’ genomes. (<bold>B</bold>) Zoom-in-view of deletion genomic coordinates at the TCRalpha locus of a representative single T-cell genome. (<bold>C</bold>) Left panel, bar plot quantification of TCRalpha (TCRa) and TCRbeta (TCRb) deletion frequencies observed in 95 sequenced single CD4+/CD8+ T-cells. Right panel, bar plot illustration of light chain (IGL) and heavy chain (IGH) deletion detection frequencies derived from single-cell sequencing of 93 CD27+/CD13+ B-cells. (<bold>D</bold>) Breakpoint analysis of TCRa deletions in CD4+/CD8+ T-cells illustrating the heterogeneity of breakpoint occurrence in genomic bins. (<bold>E</bold>) Zoom-in-view of the heterogeneity of TCRa deletion breakpoints found in X-loss T-cells identified from two representative patients tumors. (<bold>F</bold>) Pair-wise distances of genomic bins within TCRa deletion breakpoints in single T-cells found in tumors biopsies (P15 and P59), blood purified CD8+/4+ T-cells, and single-leukemic cells derived from T-cell leukemia. (<bold>G</bold>) Representative genome-wide copy number profiles of T-cells with karyotypic abnormalities. Examples shown are: gain on chromosome 16 and an interstitial deletion on chromosome nine in two different T-cells genomes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Copy number alterations in pseudo-diploid cells identified in tumor samples.</title><p>(<bold>A</bold>) Representative genome-wide copy number profiles of patient matched pseudo-diploid and cancer cells from two patients. Shaded in gray are chromosomes where pseudo-diploid CNAs are identified. (<bold>B</bold>) Heatmap illustration of copy number profiles of all identified (n = 28) pseudo-diploid single cells in analyzed tumor samples.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig1-figsupp3-v1.tif"/></fig></fig-group><p>Given the importance of T-cells in emerging immunotherapies (<xref ref-type="bibr" rid="bib51">Sharma and Allison, 2015</xref>), we performed more detailed analysis on the identified T-cells and queried whether they represent clonally expanded T-cells that have infiltrated the tumor mass, or TCRa unique, non-clonal T-cells. To gauge the specificity in detecting genetically unique T-cells using single-cell sequencing we examined the pattern of breakpoints resulting from TCRa deletions. In the purified CD4+/CD8+ T-cell nuclei (n = 95), deletion breakpoints were found distributed over 14 genomic bins and in the majority of T-cells were not shared, suggesting unique TCRa recombination events (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). Extending this breakpoint analysis to T-cells identified in patient biopsies, we found that within a given tumor none of the T-cells shared identical breakpoints, similarly suggesting that the identified T-cells were non-clonally derived and genetically distinct. This is in contrast to the breakpoints observed in nuclei derived from a T-cell leukemia which were recurrent and positionally identical across different single nuclei (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). To quantitatively corroborate these observations, we devised a breakpoint distance metric and applied it to the abovementioned T-cell groupings (Methods). Indeed, we find lower breakpoint pairwise-distance values in the single-nuclei derived from the T-cell leukemia compared to both CD8+/CD4+ T-cells and T-cells found in breast cancer biopsies (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2F</xref>). All the T-cell leukemia nuclei in this analysis shared identical breakpoints, p-value&lt;10<sup>−6</sup>, in contrast to T-cells found in tumor biopsies. In addition to the heterogeneity of the TCRa deletion breakpoints in T-cells, we observed large karyotypic abnormalities affecting some T-cell genomes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2G</xref>). These karyotypic abnormalities were represented overwhelmingly by a loss of an entire copy of the X chromosome (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) consistent with previous karyotyping studies of proliferating lymphocytes (<xref ref-type="bibr" rid="bib44">Nowinski et al., 1990</xref>). These X-loss T-cells, when found in the same patient sample, were genetically distinct at their respective TCRa locus as judged by the deletion breakpoints as well as the above mentioned breakpoint-distance metric (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E and F</xref>). Interestingly, T-cells displaying X-loss were found more frequently in estrogen receptor negative (ER-) compared to estrogen receptor positive (ER+) tumors (p-value=0.0047) (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, insert). Given that BRCA1 has been shown experimentally to be associated with the process of X-inactivation (<xref ref-type="bibr" rid="bib28">Ganesan et al., 2002</xref>) and that BRCA1-mutant tumors are mostly ER- tumors, this association is intriguing.</p><p>Additionally, we and others have reported the detection of individual, aneuploid nuclei that carry non-clonal, genetically heterogeneous CNAs termed pseudo-diploids (<xref ref-type="bibr" rid="bib41">Navin et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Demeulemeester et al., 2016</xref>). Initially identified in two triple negative primary tumors and not their matching metastasis (<xref ref-type="bibr" rid="bib41">Navin et al., 2011</xref>), here, we extend their observation to tumors from all four PAM50 subtypes studied (i.e. LumA, LumB, HER2+, and Basal) (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Interestingly, we find that some carry prototypical breast cancer CNAs such as gain of 1q and loss of 16 p (<xref ref-type="fig" rid="fig1">Figure 1F</xref> – right panel). The pseudo-diploids observed in our cohort however do not appear to be precursors to the clonal cancer cells constituting the tumor mass as they do not share their respective CNAs (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). We interpret the observation of these nuclei as a manifestation of the inherent genomic instability present in normal breast epithelial cells of cancer patients. Further analyses, across a larger number of single pseudo-diploid nuclei while also factoring somatic single-nucleotide variant (SNV) information, are required to definitively prove this.</p><p>Thus, using single-cell sequencing we were able to detect immune cells present within the tumor mass and infer their genetic heterogeneity as well as extend the identification of pseudo-diploids to all PAM50 breast cancer subtypes and observe the occurrence of cancer associated CNAs in these cells.</p></sec><sec id="s2-3"><title>Genetic heterogeneity of large copy number alterations in cancer cells and the importance of dosage</title><p>We then proceeded to analyze the genetic heterogeneity of large-scale CNAs present in sequenced single cancer nuclei. These events include CNAs larger than 3 MB as well as whole chromosome or arm level events. As a way of illustrating the data, we plot all single-nuclei copy number profiles from a given patient on the same graph. Doing so for tumor P5 (LumA), one can visually distinguish clonal from sub-clonal alterations by observing either one or multiple copy number states at any given genomic position, respectively (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). For example, losses of 8 p and 18 p (recurrent CNAs in breast cancers) are found at one copy number state and are thus clonal events (<xref ref-type="fig" rid="fig2">Figure 2A</xref> – red arrows). Alternatively, gains at 1q and 8q (also recurrent breast cancer CNAs) as well as losses on chromosomes 13 and X are found to be sub-clonal (<xref ref-type="fig" rid="fig2">Figure 2A</xref> – blue arrows). For P5, computing the fraction of the genome found to be clonal/sub-clonal using a stringent threshold (minimum 10% of cells showing sub-clonality – Materials and methods), we find P5 to be sub-clonal in over half of its genome (56% sub-clonal) (<xref ref-type="fig" rid="fig2">Figure 2A</xref> - top bar). Extending this analysis to all tumors, we find a wide range of fractional sub-clonal values with tumors showing: (1) significant (sub-clonal at ~&gt;40% genome – Ex: P5, P22, and P59), (2) moderate (5%–20% subclonal-- Ex: P14, P58, and P31) or (3) low levels of heterogeneity (subclonal at &lt;5% of genome – Ex: P16, P41, P1) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Representative examples of significant, moderate, and low level CNA heterogeneity samples, as illustrated for P5, are provided (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Copy number heterogeneity impacts a significant proportion of breast cancer genomes and occurs at regions in the genome that are biologically and clinically important.</title><p>(<bold>A</bold>) Schematic illustration of CNA heterogeneity in tumor P5. Single-cell genomes (n = 131) are plotted on the same copy number diagram. Heterogeneous/sub-clonal regions can be identified by the presence of multiple copy number states (ex: 1q and chromosome 13). Red arrows point to representative clonal alterations. Blue arrows point to representative sub-clonal alterations. (<bold>B</bold>) Quantification of copy number heterogeneity as fraction (%) of the genome found to be sub-clonal across all sequenced biopsies. (<bold>C–H</bold>) Representative chromosome wide views of identified sub-clonal CNAs affecting: regions recurrently altered in breast cancer genomes by CNAs (<bold>C</bold>), regions containing genes of therapeutic relevance (<bold>D</bold>), regions containing genes known to be affected by somatic SNVs (<bold>E</bold>), regions with experimental evidence of involvement in breast cancer metastasis (<bold>F</bold>), regions found at three or more different copy number states (<bold>G</bold>). Gray vertical bars denote the location of genes or CNAs. (<bold>H</bold>) Distant relapse-free survival curves for cases with 1q and 8q gains that are ER+ and HER2- (n = 428). Cases are stratified based on their level of 1q or 8q gain (low vs. high).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Inferred integer copy number values of all single cancer nuclei sequenced for all patients.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-51480-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Copy number heterogeneity variably affects the genomes of breast cancers.</title><p>Schematic illustration of representative tumors with varying levels of copy number heterogeneity found in the analyzed tumor cohort: significant (<bold>A</bold>), moderate (<bold>B</bold>), and low (<bold>C</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Copy number heterogeneity occurs in regions of the genome that are important and harbor biologically relevant breast cancer genes.</title><p>(<bold>A</bold>) Chromosome zoom-in-views of regions affected by copy number heterogeneity that are important in breast cancer genomes. Categories are: regions recurrently altered by CNA, regions harboring therapeutically relevant genes, regions harboring genes known to be recurrently altered by SNV, and regions harboring genes for which experimental evidence exists for importance in the metastatic process. (<bold>B</bold>) DNA-FISH validation of a selected subset of heterogeneous CNAs. The selected alterations are: Chromosome 16q and 16 p sub-clonality seen in HER2+ tumor P14 (left panel) and PIK3CA sub-clonality in a LumA tumor, P5 (right panel). (<bold>C</bold>) Distant relapse-free survival curves for all METABRIC cases with 1q/8q gains(n = 446). Within the cohort that was ER+/HER2-, survival curves are also shown for patients that are lymph node positive (LN+, n = 192) and lymph node negative (LN-, n = 236). (<bold>D</bold>) Contingency table summarizing the relationship between high- vs. low-level 1q/8q amplification and IntClust (IC) subtype1 for all METABRIC cases with 1q/8q amplification. Among high risk ER+/HER2- groups (IC 1,2,6,9)2, IC9 has the highest rate of high level 1q/8q amplifications. A t-test for proportions between IC 9 (high risk) vs IC 3 (lower risk) shows that high-level 1q/8q amplifications are statistically significantly more likely to occur in IC9 (p-value=3.021e-07).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig2-figsupp2-v1.tif"/></fig></fig-group><p>Importantly, regions found to be sub-clonal in tumor samples included regions: (1) known to be recurrently altered by CNAs (ex: 8 p and 13q), (2) harboring genes encoding therapeutic targets such as ESR1, CYP19A (<xref ref-type="bibr" rid="bib25">Ellis et al., 2012</xref>), CDK6 (<xref ref-type="bibr" rid="bib55">Turner et al., 2015</xref>), and PD-L1 (<xref ref-type="bibr" rid="bib40">Nanda et al., 2016</xref>), (3) harboring genes known to be recurrently mutated by single nucleotide variants (SNVs) such as PIK3R1, PDGFRA, and RUNX1 (<xref ref-type="bibr" rid="bib13">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib43">Nik-Zainal et al., 2016</xref>), and (4) harboring genes experimentally shown to be involved in metastasis (<xref ref-type="bibr" rid="bib57">Valiente et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Wagenblast et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Ross et al., 2015</xref>; <xref ref-type="fig" rid="fig2">Figure 2C</xref> - F and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). DNA-FISH was used to validate a selected subset of these alterations (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). Importantly, for some of the alterations, we find that the sub-clonal CNAs exist at three or more distinct copy number states in different single cells, for example, 8q gains in P5 (LumA) and P22 (Basal) (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). This may have an effect on the level of expression/dosage of genes encoded on those chromosomes and thus may affect phenotypic heterogeneity. Reasoning that the increase of dosage of genes at 8q and/or 1q might be associated with advanced disease and hence bad prognosis, we devised an analysis approach to measure the relative dosage of these events in bulk copy number datasets and test their association with patient survival in a large, carefully annotated breast cancer dataset; METABRIC (20) (Methods). Indeed, we find that 1q/8q high tumors in ER+/HER2- patients (regardless of ploidy status of the tumor genome) are associated with worst distant relapse free survival (<xref ref-type="fig" rid="fig2">Figure 2H</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>). Further, among the newly discovered breast cancer subgroups (IntClust, IC) groups, we find that 1q/8q high tumors are enriched in the IC9 subgroup which is associated with high-risk of late distant relapse (<xref ref-type="bibr" rid="bib47">Rueda et al., 2019</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>).</p><p>Together, these data show that heterogeneity of large copy number events can: (1) affect a large proportion of the genome in any given tumor, (2) exist at multiple levels (ex: dosage - three or more copy number states in the same tumor), and (3) that this heterogeneity can affect regions of the genome that are important for treatment or disease relapse.</p></sec><sec id="s2-4"><title>Multiple forms of genetic heterogeneity of focal chromosomal amplicons</title><p>Focal amplifications and deletions comprise another important class of CNAs. Prototypical driver amplifications containing ERBB2, CCND1, MYC, and CCNE1, as well as less commonly identified amplifications such as PPM1D and MDM2, were identified in our patient cohort and in some cases were clonal (i.e. identified in all single-nuclei sequenced) (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). However, as seen with larger CNAs, many tumors displayed chromosome amplifications genetic heterogeneity. For example in tumor P22 (basal), three focal amplicons encompassing the VEGFA, MYC and CCNE1 loci were found in varying proportions and in certain instances (VEGFA and CCNE1) in a mutually exclusive manner in sequenced single-nuclei (p-value=0.003 – Fisher’s Exact Test). A sub-population lacking any of the amplicons, but having lost an additional copy of the RB1 gene via a focal deletion was also identified (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref> – figure supplement B-D). Interestingly, the amplifications segregate with genetically distinct, geographically resolved tumor sub-populations (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D and E</xref>). Thus, P22 amplifications are somatically mosaic. Other examples of amplicon mosaicism include P5 (LumA) where an amplification targeting GATA6 was found only in a sub-population of cancer cells and P59 (Basal), where amplifications on multiple chromosomes (chromosomes 3, 5, 6 and 18) targeting important genes such as LOX (<xref ref-type="bibr" rid="bib18">Cox et al., 2015</xref>) and PRDM1 (<xref ref-type="bibr" rid="bib43">Nik-Zainal et al., 2016</xref>) where found in the majority of cells but absent in others (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). In total, 6 out of the 16 (37%) tumors analyzed displayed amplicon mosaicism in the form of presence/absence of one or more amplicons in different subpopulations of cancer cells.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Different forms of genetic heterogeneity in chromosomal amplifications.</title><p>(<bold>A</bold>) Representative zoom-in chromosome views of clonal prototypical breast cancer amplicons such as ERBB2 and CCND1 identified in patient samples. (<bold>B</bold>) Genome-wide copy number profiles of representative (n = 4) single-cell genomes illustrating heterogeneous amplifications in tumor P22. Profiles are annotated with distinguishing amplicons. A representative profile of a single nucleus with no amplifications, but deleted for the RB1 gene, is also noted. (<bold>C</bold>) Heatmap illustration of P22 amplicon copy number heterogeneity and the mutually exclusive nature of the CCNE1 and VEGFA amplicons - statistical significance based on Fisher’s Exact Test (p-value=0.0032, Odds ratio = 0, 95% confidence interval 0–0.44). Single-nuclei are ordered according to hierarchal clustering as illustrated in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>. Color key is according to increasing copy number states. (<bold>D</bold>) Genome-wide copy number profiles of representative single-cell genomes illustrating heterogeneous amplifications in tumor P6. Profiles with distinguishing amplifications are annotated on the figure. (<bold>E</bold>) DNA-FISH validation of somatic mosaicism of the SKIL and MYC amplicons in tumor P6. DNA-FISH data also illustrate the geographic demarcation of the amplification in the field of view. (<bold>F</bold>) Zoom-in-views of the SKIL and MYC amplicons in representative single-cells illustrating the heterogeneity in the level of chromosomal amplification in tumor P6. (<bold>G</bold>) DNA-FISH validation of low level/high-level amplification of SKIL and MYC loci inferred based on fluorescence signal intensity.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Clonal and sub-clonal Chromosomal amplicons are detectable using single-cell copy number profiling.</title><p>(<bold>A</bold>) Representative illustration of clonal, non-heterogeneous chromosomal amplifications found in analyzed patient samples. (<bold>B</bold>) Genome-wide copy number plots of representative single-cells showing heterogeneous amplifications in tumor P22. Top-left panel illustrates a cell without chromosomal amplifications having lost an additional copy of the RB1 gene via a focal deletion. Top-right panel illustrates a single cell with CCNE1 amplification. Bottom-left panel illustrates a single-cell with a MYC amplification. Bottom-right panel illustrates a single-cell amplified for the VEGFA locus. (<bold>C</bold>) Scatter plot illustration of the mutual exclusivity of the CCNE1 and VEGFA amplicons in P22. (<bold>D</bold>) Hierarchal clustering tree based on copy number alterations illustrating the association of the mosaic amplicons identified in P22 (Basal) with different, genetically distinct sub-clonal populations. (<bold>E</bold>) DNA-FISH validation of the mosaicism and mutual exclusivity of VEGFA and CCNE1 amplicons in P22.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Examples of somatic mosaicism and differential dosage of chromosomal amplifications identified in analyzed breast cancers biopsies and identification of clonal homozygous deletions in analyzed samples.</title><p>(<bold>A</bold>) Genome-wide and chromosomal zoom-in plots of representative single cells derived from tumors (P5 and P59) harboring somatically mosaic amplicons. Mosaic amplicons are annotated on the plots. (<bold>B</bold>) Zoom in chromosomal view of the heterogeneity of HER2 level of amplification/dosage identified in single-cells from P9, a HER2+ tumor. (<bold>C</bold>) DNA-FISH validation of the varying levels of HER2 amplification in P9. Heterogeneity is inferred from probe intensity. Low level and high level amplification are noted. (<bold>D</bold>) Zoom-in-views of clonal homozygous deletions identified in a subset of breast cancer genomes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig3-figsupp2-v1.tif"/></fig></fig-group><p>Presence or absence of an amplicon in single cells was not the only form of variation we observed in chromosomal amplifications. Another form of variation observed came in the form of the level (or dosage) of amplification. An example is P6 (HER2+) where different spatially resolved sub-populations were identified carrying either: (1) only ERBB2 amplification, (2) ERBB2 and SKIL amplifications, or (3) ERBB2, SKIL, and MYC amplifications (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). Importantly, for the SKIL and MYC amplicons, different single-nuclei were found to have varying levels/dosage of amplification. Where in some single-nuclei, SKIL and MYC levels reached over 60 copies, in others the level of amplification was less pronounced. For the MYC locus for example certain subpopulations contained MYC amplifications at less than 30 copies (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). This was confirmed using DNA-FISH analysis based on fluorescence signal intensity (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). This heterogeneity in amplicon level/dosage was also observed for the ERBB2 locus in another one of the six HER2 amplified tumors we analyzed (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B and C</xref>). Thus, chromosomal amplicons can exist at different levels within different single cells in a tumor mass.</p><p>We also observed homozygous deletions affecting known breast cancer genes such as MLLT4, MAP2K2, and NCoR1, among others (<xref ref-type="bibr" rid="bib13">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib43">Nik-Zainal et al., 2016</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D</xref>). However, we did not observe heterogeneity in this class of CNAs. We cannot rule out genetic heterogeneity of this form of variation since homozygous deletions are generally smaller in size than chromosomal amplifications and at the resolution of our analysis may have gone undetected. Nonetheless, our results illustrate varied forms of genetic heterogeneity in chromosomal amplicons affecting important breast cancer genes in a significant proportion of breast tumors. These observations are particularly important given that driver cancer genes commonly found in amplicons are generally perceived to be good targets for drug development (<xref ref-type="bibr" rid="bib13">Cancer Genome Atlas Network, 2012</xref>), have been found to be associated with metastatic breast cancer (<xref ref-type="bibr" rid="bib9">Bertucci et al., 2019</xref>), and because sub-clonality of amplifications is difficult to infer from bulk sequence data (especially targeted sequencing) given its quantitative nature, as opposed to qualitative nature of SNVs.</p></sec><sec id="s2-5"><title>Single-cell genome sequencing and multi-region sampling yield complementary information</title><p>Previous studies utilizing multi-region sequencing to investigate somatic SNVs in breast and lung cancer have shown that a significant proportion of the variation that is found between different spatially resolved biopsies can be detected at the sub-clonal level in one of the biopsies with deeper sequencing (<xref ref-type="bibr" rid="bib21">de Bruin et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="bib61">Yates et al., 2015</xref>). This has not been investigated in a genome-wide, unbiased manner for CNAs. For 9 of the 16 tumors analyzed, we were able to sequence and compare bulk DNA from two spatially resolved biopsies for CNAs. In concordance with previous studies, we find substantial differences in CNAs between biopsies (<xref ref-type="bibr" rid="bib61">Yates et al., 2015</xref>). Interestingly however, we find that much of the variation observed between the two biopsies can also be observed as sub-clonal variation in the single-cell data (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). For example, in tumor P22 (Basal), differences on chromosomes 8, 12, 15 and X were observed between the two bulk profiles but were also observed sub-clonally at the single-cell level (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>). Of 54 alterations differentially found in the two analyzed biopsies from the nine patients, 35 (65%) were identified in the data from single nuclei. This was observed for broad copy number events as well as focal amplifications, for example CCNE1 and GATA3 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Importantly, additional heterogeneous CNAs were detected only in the single-cell data and not in the bulk comparisons, for example variation on chromosome 1q and 1 p in P22 as well as alterations on 1q and chromosome four in P5, with the converse also being true (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Thus, in our cohort, a substantial proportion (but not all) of variation in CNAs between spatially resolved biopsies is detected at the single-cell level with higher resolution analysis and some variation is only observed at the single-cell level or via multi-region sequencing.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A substantial amount of copy number variation observed between spatially resolved biopsies identified in bulk sequencing data is captured at the single-cell level in one of the biopsies.</title><p>(<bold>A</bold>) Genome-wide copy number view of bulk copy number profiles from two different geographic biopsies (blue – biopsy analyzed at bulk and single cell level, red – biopsy analyzed only in bulk) from tumor P5 (top panel) and tumor P22 (bottom panel). Gray shading denotes variation identified at bulk level between the spatially resolved biopsies and captured in single-cell data. Yellow shading indicates variation not seen in single-cell data but found in the bulk comparison. Lavender shading indicates variation observed only at the single-cell level. (<bold>B</bold>) Chromosomal view of representative examples of spatial variation of chromosomal amplicons found heterogeneously at bulk and single-cell level. Top panel indicates % of single-cells with the respective chromosomal amplification in single-cell data.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>CNA heterogeneity identified from the analysis of two spatially resolved tumor biopsies from the same patient is commonly identified in the single-cell copy number data from one of the biopsies.</title><p>(<bold>A</bold>) Top-panel: overlay copy number profiles of two different biopsies from P22 illustrating heterogeneous CNAs (i.e. non-overlapping segments). Gray shading denotes heterogeneity between two different bulk profiles that is also captured in the single-cell data of one of the biopsies. Yellow shading denotes CNA heterogeneity identified between different bulk profiles and not detected in single-cell data. Lavender shading denotes CNA heterogeneity found only in the single-nuclei data. Lower-panel: Copy number heatmap of single-cells from P22 illustrating heterogeneity of CNA from sequenced single-cells. Cells are ordered according to copy number hierarchal clustering using Manhattan distance function and Ward’s clustering method. Top and lower panels are aligned at chromosome boundaries to allow visualization and comparison of single-cell and bulk copy number data. Heatmap color schema is illustrated to the left of the heatmap. (<bold>B and C</bold>) Same as in (<bold>a</bold>) but for tumors P5 (<bold>b</bold>) and P31 (<bold>c</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>CNA heterogeneity is associated with genetic, molecular, and clinical classifications</title><p>To associate CNA heterogeneity with molecular and clinical parameters we utilized two metrics from the single-cell data, applying stringent thresholds (Methods). The first metric is the fraction of the genome found to be sub-clonal. The second metric is the number of recurrent, sub-clonal breakpoints. We chose four discrete variables for association analysis: PAM50 subtype annotation and ploidy status (biological parameters) and HER2 and estrogen receptor status (clinical parameters). Plotting the data in bar graph format with tumors rank ordered according to increasing levels of heterogeneity while applying Wilcoxon rank order testing for associations (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>) reveals several points. (1) Tumor samples of different PAM50 cancer subtypes display variable levels of CNA heterogeneity (i.e: inter-tumor CNA heterogeneity). For example, both P9 and P16 belong to the HER2+ subtype but differ markedly in their CNA heterogeneity profiles. Similarly, both P5 and P1 belong to the LumA subtype but display notable differences in CNA heterogeneity. Thus, for any given subtype, there appears to be a range in terms of CNA heterogeneity in the analyzed samples. We cannot associate or rule out an association between heterogeneity and any particular subtype due to the size of our cohort. Increasing sample sizes as well as analyzing multiple biopsies per sample in future studies will be required to delineate this. (2) Polyploid tumors are significantly more likely to be heterogeneous on the copy number level and this relationship is unrelated to the total number of clonal alterations found in each tumor. (3) As a group ER- tumors are significantly more heterogeneous on the copy number level than ER+ tumors. Thus copy number heterogeneity is variable within breast cancer tumors of the same subtype and is associated with tumor polyploidy and ER- disease. There is one exceptional outlier, an ER+/LumA (P5) with extensive copy number and clonal heterogeneity. Interestingly, unlike most ER+ tumors, P5 is mutated for the TP53 gene (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), as are the majority of ER- tumors.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Copy number heterogeneity is associated with biological and clinical parameters and tumors can be classified according to clonal composition.</title><p>(<bold>A</bold>) Bar plot with rank order illustrating CNA heterogeneity as measured by fraction (%) of the genome found to be sub-clonal. Each tumor is denoted at the top of each bar with values of fraction (%) genome sub-clonal also annotated. Categories for association analyses are depicted in panel below. Asterisks denote categories with statistically significant associations based on Wilcoxon rank order tests (p-value=0.0229 and 0.0164 for ER- and polyploidy categories respectively). p-values were rounded and annotated in the figure panel. (<bold>B</bold>) A representative illustration of a Sanger sequencing trace of DNA from a single normal and single cancer cell from tumor P5, an ER+ tumor. Traces illustrate a G to A transition at position 7578500 of chromosome 17 resulting in a non-sense mutation in the TP53 gene. (<bold>C</bold>) Correlation analysis between fraction (%) of genome sub-clonal and the log of the tumor size (cm2) as measured by MRI. Pearson’s rank correlation p-value=0.01912. Log of the size was used given the assumption of exponential tumor growth. P5, an ER+, TP53 mutant outlier is excluded from the analysis. (<bold>D</bold>) Representative MRI images of two patient tumors analyzed in this study illustrating the inverse correlation of tumor size and fraction of genome sub-clonal in ER+ tumors. Red colored ellipses denote tumor positions. (<bold>E</bold>) Heatmap illustration of three representative tumors displaying different clonal composition patterns. Patterns are: homogenous (P16), heterogeneous with a dominant clone (P14), and heterogeneous without a dominant clone (P5). Top bar denotes tumor identity with bottom bar depicting sub-clones. Heatmap color scheme is provided to the right of the heatmap. (<bold>F</bold>) Quantification and bar plot illustration of clonal composition as explained in E.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Copy number heterogeneity is associated with polyploidy and estrogen receptor negative status and these associations are not directly related to the amount of rearrangements found in the cancer genomes of analyzed samples.</title><p>(<bold>A</bold>) Bar plot representation (with rank order) of the number of sub-clonal breakpoints and their association with different biological and clinical parameters (bottom heatmap panel). p-values for associations are rounded and displayed on the figure and are based on Wilcoxon rank order testing. None rounded values are 0.0549 and 0.0241 for ER- and polyploidy categories respectively. (<bold>B</bold>) Dot plot analysis of the relationship between CNA heterogeneity (quantified using two metrics: fraction (%) genome sub-clonal and the number of sub-clonal breakpoints) and genome rearrangement (number of clonal breakpoints). Not significant relationship is found. (<bold>C</bold>) Representative illustration of the lack of relationship between sub-clonality (% genome sub-clonal – top bar) and clonal genetic rearrangements (genome-wide copy number profiles). Both tumors are highly re-arranged with one displaying high heterogeneity (P22–53% of genome sub-clonal) while the other displays low heterogeneity (P37–9% subclonal). (<bold>D</bold>) Bar plot quantification of CNA heterogeneity and patient age of the samples analyzed in this study. No significant relationship is found. (<bold>E</bold>) Bar plot illustration of the relationship between tumor size and % genome sub-clonal. No significant association is observed when analyzing all tumor biopsies analyzed in the study. A significant-inverse correlation is found when restricting the analysis to ER+ tumors and removing the ER+/TP53 mutant tumor noted in the text. The ER+/TP53 mutant tumor is also denoted in the figure.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Clonal composition is variable in breast cancer biopsies and can be used in the classification of tumors.</title><p>Heatmap illustration (left panel) and bar plot quantification (right panel) of clonal composition in representative breast tumors illustrating: (<bold>A</bold>) homogenous tumors with one dominant clone, (<bold>B</bold>) heterogeneous tumors with multiple sub-clones but with one clone dominant over others (dominant = representative of over 50% of cancer cells), and (<bold>C</bold>) heterogeneous tumors where many sub-clones exit with none being dominant in composition. Top bar denotes tumor. Bottom bar denotes clone.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-51480-fig5-figsupp2-v1.tif"/></fig></fig-group><p>We also attempted to associate copy number heterogeneity across all samples with continuous variables such as patient age and tumor size and found no significant relationships (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). However, when restricting the analysis to ER+ tumors (and excluding the ER+/TP53 mutated case) we find a relationship where tumor size and CNA heterogeneity are inversely correlated (p-value=0.02793). The largest four tumors (measuring at more than 10 cm2) display the least amount of CNA heterogeneity (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). This could be explained by the expansion and clonal sweep of a dominant clone in these tumors that is then captured when biopsying a geographically restricted region of a large tumor mass.</p><p>Lastly, we examined the clonal composition of cancer cells from analyzed tumor samples (i.e. # of genetically distinct clones in a given sample and their relative frequencies) and find that tumor samples in general conform to three different clonal classes: (1) homogenous tumors where only a single clone is observed, found only in ER+ tumors; (2) heterogeneous tumors where multiple clones exist but with one clone dominant over others (i.e. dominant &gt;50%), a pattern found throughout the cohort subtypes; and (3) heterogeneous tumors where many clones are found at varying frequencies with none of them being dominant, mainly in ER- tumors (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We provide a comprehensive analysis of breast cancer copy number alterations at the single cell level, and in the process, make many novel observations regarding the genetic heterogeneity of breast tumors. First, we observe an association between ER- tumors and T-cells exhibiting X-chromosome loss. This observation is at present of unclear clinical significance, but nevertheless might be a useful marker for this subtype of disease. Second, we observe pseudo-diploid single cells in the majority of our studied tumors, across different PAM50 subtypes, providing further evidence for the existence of such cells in breast cancer tissue. This, coupled with the observation of cancer-specific alterations (e.g. 1q gain and 16q loss) in these cells raises the question of whether these cells are a manifestation of the intrinsic genomic instability of the mammary epithelial cells of breast cancer patients and whether their detection might be useful in early stage risk assessment. Third, we observe profound genetic heterogeneity in CNAs affecting genes and regions with known biological relevance in breast cancer, such as genes associated with metastasis and therapeutic response. Thus, many cancer phenotypes might result from the selection for sub-clonal CNAs. Fourth, we find that CNA heterogeneity is not binary (i.e. sub-clonal or clonal). CNAs can be found at different copy numbers in different populations of cells and that this, in the case of 1q/8q gains is associated with clinical outcome, likely a consequence of dosage dependent biology. Fifth, the observation of mosaicism in recurrent driver amplicons in a significant proportion of tumors has clinical implications given that driver amplicon genes are often targets for drug development (e.g., ERBB2, MET, and EGFR) and have been proposed to be good targets for drug development in breast cancer (<xref ref-type="bibr" rid="bib13">Cancer Genome Atlas Network, 2012</xref>). Further, we find additional layers of heterogeneity in this class of CNAs: the presence or absence of an amplicon and variation in the level/dosage of amplification, which might be the result of extra-chromosomal amplicon instability (<xref ref-type="bibr" rid="bib56">Turner et al., 2017</xref>). This is of importance given that recent studies have provided evidence for a role of variation in gene dosage in therapeutic resistance to targeted therapy (<xref ref-type="bibr" rid="bib60">Xue et al., 2017</xref>). Sixth, the single-cell data show that a significant proportion, but not all, of the heterogeneity in CNAs found differentially between two spatially resolved biopsy samples is also captured at the single-cell level in one of the biopsies. Importantly, some variation is captured only in the single-cell data and not in the bulk comparisons. This provides a rationale for performing both spatial sampling of tumors and deep analysis of biopsy material for precision medicine applications (<xref ref-type="bibr" rid="bib61">Yates et al., 2015</xref>). Seventh, we see somewhat of an inverse correlation between tumor size and CNA heterogeneity in ER+ tumors, many of which present as a single large clone. Thus, for such large ER+ tumors, extensive spatial multi-region sampling might be necessary to capture a true picture of a tumor’s genetic heterogeneity. Eight, the association of CNA heterogeneity with parameters such as polyploidy and ER- status provides an indirect association of heterogeneity with clinical outcome since both parameters have been shown to associate with a worse prognosis (<xref ref-type="bibr" rid="bib14">Carey et al., 2006</xref>; <xref ref-type="bibr" rid="bib45">Pinto et al., 2017</xref>). Ninth, we observe that some tumors exhibit a multitude of sub-clones with no single sub-clone being dominant (largely observed in ER- tumors). This raises questions regarding the importance of clonal cooperation in the growth and evolution of breast tumors, an area for which experimental evidence has recently emerged (<xref ref-type="bibr" rid="bib38">Marusyk et al., 2014</xref>). All of the above mentioned findings provide novel observations upon which more focused investigations can be based (ex: X-loss in ER- tumors and pseudo-diploid cells) as well as a solid foundation for future, more expansive studies of CNA heterogeneity in breast, as well as other cancers.</p><p>Importantly, in contrast to bulk sequencing where elegant studies have used deep sequencing information to enable phasing and inference of genetic heterogeneity and clonality (<xref ref-type="bibr" rid="bib50">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Nik-Zainal et al., 2012</xref>), our study highlights the power inherent in single-cell genomic investigations for the direct observation and quantification of genetic heterogeneity. Most of the novel observations revealed by our study would not have been possible were it not for the single-cell nature of the data. For example, the identification of T-cells with X-chromosome losses and their association with ER- disease, as well as the detection and quantification of pseudo-diploid cells would have been obscured by bulk genomic analysis. Similarly the observation that CNAs can be found at more than two distinct copy number states, which we show is associated with clinical outcome, and the identification of somatic amplicon mosaicism in a substantial proportion of breast cancer biopsies is the result of the single-cell resolution of the data and importantly, has been missed by many prior bulk genomic studies. Thus, the results provide a strong rationale for the continued investment in the development of single-cell genomic technologies (which have lagged behind single-cell transcriptomic technologies) and their utilization in the study of tumor genomes (<xref ref-type="bibr" rid="bib8">Baslan and Hicks, 2017</xref>) to complement bulk sequencing efforts. This will require developing approaches that help in: scaling single-cell genome library construction as well as reducing costs (for example via the implementation of microfluidics) (<xref ref-type="bibr" rid="bib32">Laks et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Li et al., 2020</xref>), pairing single cell genome with single cell transcriptome information (<xref ref-type="bibr" rid="bib23">Dey et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Macaulay et al., 2015</xref>), and working with formalin fixed paraffin embedded specimen (<xref ref-type="bibr" rid="bib31">Jin et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Martelotto et al., 2017</xref>), challenges which many groups have taken efforts to address. Ultimately, single-cell genomic investigations will play an important role in advancing our knowledge of breast cancer genetics and heterogeneity and in the process advance our knowledge of the genetics and biology of the disease and help in its clinical management.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Patient cohort and tissue samples</title><p>Tissue samples were collected from 16 patients enrolled on two, neoadjuvant - phase II, open-label clinical trails conducted by the Brown University Oncology Group (BrUOG): BrUOG 211B and BrUOG 211A. Two fresh, pre-treatment core biopsies were obtained per patient, placed into optimal cutting temperature (OCT) and frozen at −80Co for subsequent processing. Patient sample associated metadata (ex: age, ER/PR/HER2 status, among other variables) are provided in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p></sec><sec id="s4-2"><title>RNA-Seq library generation, sequencing and analysis</title><p>RNA-sequencing libraries we generated and sequenced as previously described (<xref ref-type="bibr" rid="bib58">Varadan et al., 2016</xref>). For sample subtyping, a nearest centroid classifier was implemented using log2 transformed gene expression data aligned on PAM50 list for all BrUOG samples (n = 127) where RNA-seq data was available.</p></sec><sec id="s4-3"><title>Sample processing and flow cytometry for single-nuclei capture</title><p>Nuclei isolation from frozen cores was achieved by finely mincing frozen tissue, at room temperature, in 1.0 mL of NST-DAPI buffer as previously described (<xref ref-type="bibr" rid="bib6">Baslan et al., 2012</xref>). Prior to sorting, nuclei suspensions were filtered with a 5 mL Falcon round-bottom tube with a cell-trainer cap and kept on wet-ice for a minimum of 30 min. Single-cell sorting was performed using a FACS AriaIIU SORP instrument (BD Biosciences) with the ACDU option (Automated Cell Deposition Unit). DAPI signal was detected by a 355 mM UV laser (450/50 band-pass filter). For tumors with bimodal ploidy distributions (indicative of polyploidy), single-nuclei were sorted from both the diploid and polyploidy distributions for processing. For tumors with only a unimodal diploid distribution, diploid nuclei were sorted and processed. Single-nuclei were deposited into 96-well plates pre-loaded with 9 uL of cell lysis buffer per well as previously described (<xref ref-type="bibr" rid="bib6">Baslan et al., 2012</xref>). All sorted plates were processed on the same day for single-cell genome amplification.</p></sec><sec id="s4-4"><title>Single-nuclei whole genome amplification and sequencing</title><p>Single-nuclei were amplified using WGA4 (Sigma-Aldrich) as per manufacturers protocol. WGA DNA was sonicated to + / - 300 bps using the Covaris instrument (duty cycle −10%, Intensity −4, cycles/burst – 200 and time 80 s). WGA sonicated DNA (processed in 96 well format, i.e. 96 nuclei per plate) was end-repaired, A-tailed and ligated to 96 custom in-house developed adaptors (<xref ref-type="bibr" rid="bib30">Iossifov et al., 2012</xref>). Adaptor ligated products were purified using AMPure XP beads (Beckman Coulter). All adaptor ligated single-cell barcoded libraries (n = 96) were pooled, amplified and quantified for sequencing. All pools were sequenced on the HiSeq instrument using either SR76 or SR101 sequencing.</p></sec><sec id="s4-5"><title>Single-nuclei CNA analysis of cancer cells</title><p>Single-nuclei copy number information was inferred from sequencing data as previously described (<xref ref-type="bibr" rid="bib6">Baslan et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Baslan et al., 2015</xref>). In brief, sequence reads were mapped to human reference genome (reference hg19), sorted, PCR duplicated removed, and subsequently indexed. Uniquely mapped reads were counted in genomic bins using a previously developed algorithm; Varbin (<xref ref-type="bibr" rid="bib41">Navin et al., 2011</xref>). Read counts were then normalized and segmentation performed using circular binary segmentation (CBS). To retrieve absolute (integer) copy number information, we utilized an algorithm that assigns ploidy and associated copy number states in single-nuclei data by utilizing a least-squares fitting algorithm used in determining a multiplier value that minimizes the variance from integer copy number states (<xref ref-type="bibr" rid="bib7">Baslan et al., 2015</xref>). All inferred integer copy number values of single-nuclei for all tumors (at bin sizes of ~600 KB, dividing the genome in 5000 bins/5 k) are provided in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. For analysis of fraction (%) of genome sub-clonal, we developed a pipeline where for each genomic bin we counted the number of observable copy number states found in all single-nuclei sequenced from a given patient sample. For a bin to be called sub-clonal, we required the observation of a particular copy number state in any genomic bin in at least 10% of sequenced single-nuclei. Summing all sub-clonal bins and dividing by the total number of bins is used to derive the metric: % genome sub-clonal. For this analysis, the genome was divided into five thousand bins (i.e. bin resolution of ~600 kb). Derivation of breakpoint information was performed as described previously (<xref ref-type="bibr" rid="bib2">Alexander et al., 2018</xref>). In brief, bin positions at which changes in segmented copy number states occur were annotated across all sequenced single-nuclei. To account for the inherent uncertainty in breakpoint bin positioning in segmentation algorithms we utilized a window of 3 bins where a breakpoint in any of those bins was treated as equal (i.e. same breakpoint). Histograms of breakpoint distributions were then constructed and any breakpoint found in less than 90% and more than 10% of all sequenced nuclei from a given tumor sample was deemed sub-clonal. All breakpoints found in over 90% of single-nuclei data were annotated as clonal pins/breakpoints.</p></sec><sec id="s4-6"><title>Bulk DNA library generation, sequencing and analysis</title><p>Bulk DNA was purified using phenol-chloroform extraction as previously described (<xref ref-type="bibr" rid="bib7">Baslan et al., 2015</xref>). Bulk DNA was sonicated, end-repaired, A-tailed, and ligated to custom in-house developed adaptors. Libraries were enriched, quantified, and pooled at equimolar concentration for sequencing on the HiSeq instrument. Bulk copy number sequence analysis was performed as described above with the exception that the multiplier, utilized in the least squares-fitting algorithm, was constrained by values derived from flow cytometry data (i.e. ploidy) to achieve absolute copy number values.</p></sec><sec id="s4-7"><title>T-cell and B-cell sample processing and analysis</title><p>Purified CD8+/CD4+ T-cells and CD19+/CD27+ memory B-cells purified cells were purchased from ALLCELLS (California, USA). Cells were thawed on ice, pelleted, and re-suspended in NST-DAPI buffer for nuclei isolation. Single-nuclei (n = 96) from both sets were sorted from the diploid peak, genome amplified, and processed for multiplex sequencing as described for the cancer biopsies above.</p></sec><sec id="s4-8"><title>T-cell breakpoint analysis</title><p>The distance between TCR deletions in two nuclei is defined to be the number of bins offset between the left breakpoints plus the number of bins offset between the right breakpoints. In order to normalized for depth and noise, nuclei with at least 1 million mapped reads were each down-sampled to exactly 1 million mapped reads and re-segmented. All T-cell leukemia nuclei share identical breakpoint bin positions. An equal number of T-cell nuclei found in breast cancer tissue with over 1 million uniquely mapped reads included in this analysis were randomly sampled in proportional sets, 1 million times. None of these 1 million random samples had all nuclei sharing identical breakpoints indicating a p-value of &lt;10<sup>−6</sup>.</p></sec><sec id="s4-9"><title>DNA-FISH analysis</title><p>FISH analysis was performed on frozen section using home-brew Probe. The probe mix consisted of BAC clones containing the full length target gene and labeled with Red, Green, or Orange-dUTP as indicated in in figure legends. DNA was labeled by nick translation using fluorochrome-conjugated dUTPs from Enzo Life Sciences Inc, supplied by Abbott Molecular Inc Tissue processing, hybridization, post-hybridization washing, and fluorescence detection were performed according to standard procedures established at the MSKCC Molecular Cytogenetics Core Facility. Slides were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped with CoolCube 1 CCD camera controlled by Isis 5.5.10 imaging software (MetaSystems Group Inc, Waltham, MA). Prior to hybridization on tissue section, the probe-mix was hybridized on peripheral blood from normal healthy male to ensure locus specificity. Following hybridization, the tissue was scanned through 63X to assess signal pattern and representative regions imaged (each image was a compressed/merged stack of 12 z-section images taken at 0.5 micron intervals under the Red, Green and Orange filter respectively). Analysis was performed on captured images.</p></sec><sec id="s4-10"><title>MRI imaging</title><p>Bilateral breast MRI evaluation with a dedicated breast coil (without compression) was done on a 1.5 Tesla magnet. Images were collected for 6 min at 1 min intervals for following bolus IV gadolinium administration (0.1 mmol/kg). Images were Axial 3D SPGR fat-suppressed T1-weighted. A board certified radiologist interpreted the images.</p></sec><sec id="s4-11"><title>Bulk copy number analysis of METABRIC datasets for survival analysis</title><p>We used published copy number data from the METABRIC cohort (<xref ref-type="bibr" rid="bib19">Curtis et al., 2012</xref>) and associated distant relapse free survival data to assess the association between higher dosages of 1q or 8q and patient outcomes. For 1992 cases (from the discovery and validation sets in the initial study), segmented absolute copy number calls were derived using circular binary segmentation. Specifically, the copy number data were smoothed and analyzed with the R package DNAcopy using default parameters, followed by applying the MergeLevels algorithm to the segmented data. In order to remove the dependence between cellularity and the proportion of alterations, we employed different thresholds for calling alterations and high-levels events according to the cellularity of each sample, as previously reported. The clinical outcome analysis included only cases from the original cohort that possessed a 16q loss and either a 1q gain or an 8q gain (446 cases total). Copy number status of the three chromosome arms of interest (1q, 8q, and 16q) was determined by calculating a weighted arithmetic mean of the segments comprising the chromosome arm. In order to allow for parallel analysis of diploid and polyploid tumors, the mean copy number for the 16q chromosome arm (loss of 16q is cytogenetically linked to 1q/8q gain) was used to normalize the degree of gain present in the 1q and 8q arms. For each case, the maximum of the normalized mean copy number from either 1q or 8q was used for downstream analysis. Cases were divided into those with evidence of high-level Gain on 1q or 8q (66 cases, normalized CN &gt;1.5) and those with low-level Gain (380 cases). Kaplan-Meier analysis was performed to compare these groups within all breast cancer patients using time to distant relapse as the outcome. Since overexpression of the ER and HER2 receptors and lymph node status are strong independent predictors of clinical outcome, we also stratified our findings by ER/HER2 status and lymph node status. In a Cox proportional hazards models that accounts for other clinical covariates (age, grade, size, LN status, ER, PR, and HER2 expression) 1q/8q ratio was not independently significant.</p></sec><sec id="s4-12"><title>Statistical analysis</title><p>All statistical tests were performed using the statistical package R. For the X-loss in T-cells comparison in ER- and ER+ disease a chi-square test was used. For analysis of mutual exclusivity of CCNE1 and VEGFA amplification (copy number higher than 5) in P22, Fisher’s Exact Test was used with the alterative hypothesis that true odds ratio is less than 1. For correlations of copy number heterogeneity with biological and clinical variables, Wilcoxon rank order tests were implemented. Spearman rank was used to study the association of tumor size with CNA heterogeneity in ER+ cases. p-values are provided for all statistical tests either in the figures, figure legends, or both.</p></sec><sec id="s4-13"><title>Sanger sequencing</title><p>Normal and cancer single-nuclei WGA DNA (n = 10 for each category) was subjected to PCR amplification of tp53 exons followed by Sanger sequencing. In brief, 50 ng of WGA DNA for 10 nuclei per above category were amplified in a PCR reaction using 1X Amplitaq 360 master mix with 0.2 nM of forward and reverse primers. Resultant PCR products were sequenced using standard Sanger sequencing protocols. A Sanger trace from one representative WGA DNA (one for each normal and cancer) is illustrated in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</p></sec><sec id="s4-14"><title>Data and code availability</title><p>Data generated for this study are available thought Short Read Archive (SRA) under BioProject accession number PRJNA555560. All single-cell raw sequencing data were processed using code provided in detailed in <xref ref-type="bibr" rid="bib6">Baslan et al. (2012)</xref>. The R Source code for the calculation of % of genome sub-clonal is included as <xref ref-type="supplementary-material" rid="scode1">Source code 1</xref>. The R source code used for the derivation of clonal/sub-clonal pins, as described in Materials and methods section, is available on GitHub at <ext-link ext-link-type="uri" xlink:href="https://github.com/jysonganan/SCclust/blob/master/R/selectpin.R">https://github.com/jysonganan/SCclust/blob/master/R/selectpin.R</ext-link>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Pamela Moody of the CSHL flow cytometry core for assistance in single-cell sorting. We thank Michael Berger, Maurizio Scaltriti, Ben Stanger, and John Morris The Fourth for critical reading of the manuscript and feedback. This work was supported by grants to MW from the Department of Defense (W81XWH-11–10747), the Breast Cancer Research Foundation (BCRF), and the McFarland Fund. MW is an American Cancer Society Research Professor. JH is supported by the BCRF and the Susan G Komen Foundation (IIR13265578). TB is supported the by the William C and Joyce C O’Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative. MSK Molecular Cytogenetics Core is supported by the NIH-CCSG (P30 -CA008748).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an employee of Philips Research North America.</p></fn><fn fn-type="COI-statement" id="conf3"><p>is affiliated with House Gordon Software Company LTD. The author has no other competing interests to declare.</p></fn><fn fn-type="COI-statement" id="conf4"><p>is an employee of Philips Research North America.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con3"><p>Software, Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con5"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation, Software, Formal analysis, Supervision, Visualization</p></fn><fn fn-type="con" id="con11"><p>Software, Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Data curation, Software, Formal analysis, Visualization</p></fn><fn fn-type="con" id="con13"><p>Data curation</p></fn><fn fn-type="con" id="con14"><p>Formal analysis</p></fn><fn fn-type="con" id="con15"><p>Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con16"><p>Methodology</p></fn><fn fn-type="con" id="con17"><p>Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con18"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con19"><p>Data curation, Visualization</p></fn><fn fn-type="con" id="con20"><p>Data curation, Formal analysis, Supervision</p></fn><fn fn-type="con" id="con21"><p>Resources, Data curation, Software, Formal analysis, Supervision, Visualization</p></fn><fn fn-type="con" id="con22"><p>Supervision, Project administration</p></fn><fn fn-type="con" id="con23"><p>Resources, Supervision, Investigation</p></fn><fn fn-type="con" id="con24"><p>Formal analysis, Supervision, Funding acquisition, Investigation, Methodology</p></fn><fn fn-type="con" id="con25"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Methodology</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: Informed consent for sample acquisition and sequencing was obtained per the BrUOG and Case Western University Institutional Review Boards by Dr. Lyndsay Harris as part of clinical trial BrUOG 211A/B. The described study was also approved by the CSHL Institutional Review Board under Project IRB-12-017 titled &quot;Single Cell Exome &amp; Copy Number Profiling in Cancer&quot; lead by Dr. James Hicks.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>R Source code for the calculation of % of genome sub-clonal.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-51480-code1-v1.r"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-51480-transrepform-v1.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Data generated for this study are available thought Short Read Archive (SRA) under BioProject accession number PRJNA555560.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Baslan</surname><given-names>B</given-names></name><name><surname>Kendall</surname><given-names>J</given-names></name><name><surname>Volyanskyy</surname><given-names>K</given-names></name><name><surname>McNamara</surname><given-names>K</given-names></name><name><surname>Cox</surname><given-names>H</given-names></name><name><surname>D'Italia</surname><given-names>S</given-names></name><name><surname>Ambrosio</surname><given-names>F</given-names></name><name><surname>Riggs</surname><given-names>M</given-names></name><name><surname>Rodgers</surname><given-names>L</given-names></name><name><surname>Leotta</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Gularte-Mérida</surname><given-names>R</given-names></name><name><surname>Chadalavada</surname><given-names>K</given-names></name><name><surname>Nanjangud</surname><given-names>G</given-names></name><name><surname>Varadan</surname><given-names>V</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Curtis</surname><given-names>C</given-names></name><name><surname>Krasnitz</surname><given-names>A</given-names></name><name><surname>Dimitrova</surname><given-names>N</given-names></name><name><surname>Harris</surname><given-names>L</given-names></name><name><surname>Wigler</surname><given-names>M</given-names></name><name><surname>Hicks</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Single-cell genome sequencing of breast cancer</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA555560/">PRJNA555560</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeyinka</surname> <given-names>A</given-names></name><name><surname>Baldetorp</surname> <given-names>B</given-names></name><name><surname>Mertens</surname> <given-names>F</given-names></name><name><surname>Olsson</surname> <given-names>H</given-names></name><name><surname>Johannsson</surname> <given-names>O</given-names></name><name><surname>Heim</surname> <given-names>S</given-names></name><name><surname>Pandis</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Comparative cytogenetic and DNA flow cytometric analysis of 242 primary breast carcinomas</article-title><source>Cancer Genetics and Cytogenetics</source><volume>147</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/S0165-4608(03)00190-0</pub-id><pub-id pub-id-type="pmid">14580772</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname> <given-names>J</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>McIndoo</surname> <given-names>J</given-names></name><name><surname>Rodgers</surname> <given-names>L</given-names></name><name><surname>Aboukhalil</surname> <given-names>R</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Stepansky</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>G</given-names></name><name><surname>Chobardjiev</surname> <given-names>L</given-names></name><name><surname>Riggs</surname> <given-names>M</given-names></name><name><surname>Cox</surname> <given-names>H</given-names></name><name><surname>Hakker</surname> <given-names>I</given-names></name><name><surname>Nowak</surname> <given-names>DG</given-names></name><name><surname>Laze</surname> <given-names>J</given-names></name><name><surname>Llukani</surname> <given-names>E</given-names></name><name><surname>Srivastava</surname> <given-names>A</given-names></name><name><surname>Gruschow</surname> <given-names>S</given-names></name><name><surname>Yadav</surname> <given-names>SS</given-names></name><name><surname>Robinson</surname> <given-names>B</given-names></name><name><surname>Atwal</surname> <given-names>G</given-names></name><name><surname>Trotman</surname> <given-names>LC</given-names></name><name><surname>Lepor</surname> <given-names>H</given-names></name><name><surname>Hicks</surname> <given-names>J</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name><name><surname>Krasnitz</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Utility of Single-Cell genomics in diagnostic evaluation of prostate Cancer</article-title><source>Cancer Research</source><volume>78</volume><fpage>348</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1138</pub-id><pub-id pub-id-type="pmid">29180472</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname> <given-names>RH</given-names></name><name><surname>Valero</surname> <given-names>V</given-names></name><name><surname>Hortobagyi</surname> <given-names>GN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Emerging targeted therapies for breast Cancer</article-title><source>Journal of Clinical Oncology</source><volume>28</volume><fpage>3366</fpage><lpage>3379</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.4011</pub-id><pub-id pub-id-type="pmid">20530283</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arteaga</surname> <given-names>CL</given-names></name><name><surname>Engelman</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ERBB receptors: from oncogene discovery to basic science to mechanism-based Cancer therapeutics</article-title><source>Cancer Cell</source><volume>25</volume><fpage>282</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.02.025</pub-id><pub-id pub-id-type="pmid">24651011</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerji</surname> <given-names>S</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Rangel-Escareno</surname> <given-names>C</given-names></name><name><surname>Brown</surname> <given-names>KK</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Frederick</surname> <given-names>AM</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Sivachenko</surname> <given-names>AY</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name><name><surname>Cortes</surname> <given-names>ML</given-names></name><name><surname>Fernandez-Lopez</surname> <given-names>JC</given-names></name><name><surname>Peng</surname> <given-names>S</given-names></name><name><surname>Ardlie</surname> <given-names>KG</given-names></name><name><surname>Auclair</surname> <given-names>D</given-names></name><name><surname>Bautista-Piña</surname> <given-names>V</given-names></name><name><surname>Duke</surname> <given-names>F</given-names></name><name><surname>Francis</surname> <given-names>J</given-names></name><name><surname>Jung</surname> <given-names>J</given-names></name><name><surname>Maffuz-Aziz</surname> <given-names>A</given-names></name><name><surname>Onofrio</surname> <given-names>RC</given-names></name><name><surname>Parkin</surname> <given-names>M</given-names></name><name><surname>Pho</surname> <given-names>NH</given-names></name><name><surname>Quintanar-Jurado</surname> <given-names>V</given-names></name><name><surname>Ramos</surname> <given-names>AH</given-names></name><name><surname>Rebollar-Vega</surname> <given-names>R</given-names></name><name><surname>Rodriguez-Cuevas</surname> <given-names>S</given-names></name><name><surname>Romero-Cordoba</surname> <given-names>SL</given-names></name><name><surname>Schumacher</surname> <given-names>SE</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Thompson</surname> <given-names>KM</given-names></name><name><surname>Uribe-Figueroa</surname> <given-names>L</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Polyak</surname> <given-names>K</given-names></name><name><surname>Sgroi</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Jimenez-Sanchez</surname> <given-names>G</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Melendez-Zajgla</surname> <given-names>J</given-names></name><name><surname>Toker</surname> <given-names>A</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Hidalgo-Miranda</surname> <given-names>A</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sequence analysis of mutations and translocations across breast Cancer subtypes</article-title><source>Nature</source><volume>486</volume><fpage>405</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1038/nature11154</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baslan</surname> <given-names>T</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>Rodgers</surname> <given-names>L</given-names></name><name><surname>Cox</surname> <given-names>H</given-names></name><name><surname>Riggs</surname> <given-names>M</given-names></name><name><surname>Stepansky</surname> <given-names>A</given-names></name><name><surname>Troge</surname> <given-names>J</given-names></name><name><surname>Ravi</surname> <given-names>K</given-names></name><name><surname>Esposito</surname> <given-names>D</given-names></name><name><surname>Lakshmi</surname> <given-names>B</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name><name><surname>Navin</surname> <given-names>N</given-names></name><name><surname>Hicks</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genome-wide copy number analysis of single cells</article-title><source>Nature Protocols</source><volume>7</volume><fpage>1024</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.039</pub-id><pub-id pub-id-type="pmid">22555242</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baslan</surname> <given-names>T</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>Ward</surname> <given-names>B</given-names></name><name><surname>Cox</surname> <given-names>H</given-names></name><name><surname>Leotta</surname> <given-names>A</given-names></name><name><surname>Rodgers</surname> <given-names>L</given-names></name><name><surname>Riggs</surname> <given-names>M</given-names></name><name><surname>D'Italia</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>G</given-names></name><name><surname>Yong</surname> <given-names>M</given-names></name><name><surname>Miskimen</surname> <given-names>K</given-names></name><name><surname>Gilmore</surname> <given-names>H</given-names></name><name><surname>Saborowski</surname> <given-names>M</given-names></name><name><surname>Dimitrova</surname> <given-names>N</given-names></name><name><surname>Krasnitz</surname> <given-names>A</given-names></name><name><surname>Harris</surname> <given-names>L</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name><name><surname>Hicks</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Optimizing sparse sequencing of single cells for highly multiplex copy number profiling</article-title><source>Genome Research</source><volume>25</volume><fpage>714</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1101/gr.188060.114</pub-id><pub-id pub-id-type="pmid">25858951</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baslan</surname> <given-names>T</given-names></name><name><surname>Hicks</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Unravelling biology and shifting paradigms in Cancer with single-cell sequencing</article-title><source>Nature Reviews Cancer</source><volume>17</volume><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.58</pub-id><pub-id pub-id-type="pmid">28835719</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertucci</surname> <given-names>F</given-names></name><name><surname>Ng</surname> <given-names>CKY</given-names></name><name><surname>Patsouris</surname> <given-names>A</given-names></name><name><surname>Droin</surname> <given-names>N</given-names></name><name><surname>Piscuoglio</surname> <given-names>S</given-names></name><name><surname>Carbuccia</surname> <given-names>N</given-names></name><name><surname>Soria</surname> <given-names>JC</given-names></name><name><surname>Dien</surname> <given-names>AT</given-names></name><name><surname>Adnani</surname> <given-names>Y</given-names></name><name><surname>Kamal</surname> <given-names>M</given-names></name><name><surname>Garnier</surname> <given-names>S</given-names></name><name><surname>Meurice</surname> <given-names>G</given-names></name><name><surname>Jimenez</surname> <given-names>M</given-names></name><name><surname>Dogan</surname> <given-names>S</given-names></name><name><surname>Verret</surname> <given-names>B</given-names></name><name><surname>Chaffanet</surname> <given-names>M</given-names></name><name><surname>Bachelot</surname> <given-names>T</given-names></name><name><surname>Campone</surname> <given-names>M</given-names></name><name><surname>Lefeuvre</surname> <given-names>C</given-names></name><name><surname>Bonnefoi</surname> <given-names>H</given-names></name><name><surname>Dalenc</surname> <given-names>F</given-names></name><name><surname>Jacquet</surname> <given-names>A</given-names></name><name><surname>De Filippo</surname> <given-names>MR</given-names></name><name><surname>Babbar</surname> <given-names>N</given-names></name><name><surname>Birnbaum</surname> <given-names>D</given-names></name><name><surname>Filleron</surname> <given-names>T</given-names></name><name><surname>Le Tourneau</surname> <given-names>C</given-names></name><name><surname>André</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genomic characterization of metastatic breast cancers</article-title><source>Nature</source><volume>569</volume><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1056-z</pub-id><pub-id pub-id-type="pmid">31118521</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname> <given-names>S</given-names></name><name><surname>Hou</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Yong</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>B</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Gao</surname> <given-names>S</given-names></name><name><surname>Mao</surname> <given-names>Y</given-names></name><name><surname>Dong</surname> <given-names>J</given-names></name><name><surname>Zhu</surname> <given-names>P</given-names></name><name><surname>Xiu</surname> <given-names>D</given-names></name><name><surname>Yan</surname> <given-names>L</given-names></name><name><surname>Wen</surname> <given-names>L</given-names></name><name><surname>Qiao</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>F</given-names></name><name><surname>Fu</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single-cell multiomics sequencing and analyses of human colorectal Cancer</article-title><source>Science</source><volume>362</volume><fpage>1060</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1126/science.aao3791</pub-id><pub-id pub-id-type="pmid">30498128</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolhaqueiro</surname> <given-names>ACF</given-names></name><name><surname>Ponsioen</surname> <given-names>B</given-names></name><name><surname>Bakker</surname> <given-names>B</given-names></name><name><surname>Klaasen</surname> <given-names>SJ</given-names></name><name><surname>Kucukkose</surname> <given-names>E</given-names></name><name><surname>van Jaarsveld</surname> <given-names>RH</given-names></name><name><surname>Vivié</surname> <given-names>J</given-names></name><name><surname>Verlaan-Klink</surname> <given-names>I</given-names></name><name><surname>Hami</surname> <given-names>N</given-names></name><name><surname>Spierings</surname> <given-names>DCJ</given-names></name><name><surname>Sasaki</surname> <given-names>N</given-names></name><name><surname>Dutta</surname> <given-names>D</given-names></name><name><surname>Boj</surname> <given-names>SF</given-names></name><name><surname>Vries</surname> <given-names>RGJ</given-names></name><name><surname>Lansdorp</surname> <given-names>PM</given-names></name><name><surname>van de Wetering</surname> <given-names>M</given-names></name><name><surname>van Oudenaarden</surname> <given-names>A</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name><name><surname>Kranenburg</surname> <given-names>O</given-names></name><name><surname>Foijer</surname> <given-names>F</given-names></name><name><surname>Snippert</surname> <given-names>HJG</given-names></name><name><surname>Kops</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ongoing chromosomal instability and karyotype evolution in human colorectal Cancer organoids</article-title><source>Nature Genetics</source><volume>51</volume><fpage>824</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0399-6</pub-id><pub-id pub-id-type="pmid">31036964</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname> <given-names>Y</given-names></name><name><surname>Crowther</surname> <given-names>J</given-names></name><name><surname>Pastor</surname> <given-names>T</given-names></name><name><surname>Abbasi Asbagh</surname> <given-names>L</given-names></name><name><surname>Baietti</surname> <given-names>MF</given-names></name><name><surname>De Troyer</surname> <given-names>M</given-names></name><name><surname>Vazquez</surname> <given-names>I</given-names></name><name><surname>Talebi</surname> <given-names>A</given-names></name><name><surname>Renzi</surname> <given-names>F</given-names></name><name><surname>Dehairs</surname> <given-names>J</given-names></name><name><surname>Swinnen</surname> <given-names>JV</given-names></name><name><surname>Sablina</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism</article-title><source>Cancer Cell</source><volume>29</volume><fpage>751</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.04.003</pub-id><pub-id pub-id-type="pmid">27165746</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Network</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Comprehensive molecular portraits of human breast tumours</article-title><source>Nature</source><volume>490</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nature11412</pub-id><pub-id pub-id-type="pmid">23000897</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname> <given-names>LA</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Livasy</surname> <given-names>CA</given-names></name><name><surname>Dressler</surname> <given-names>LG</given-names></name><name><surname>Cowan</surname> <given-names>D</given-names></name><name><surname>Conway</surname> <given-names>K</given-names></name><name><surname>Karaca</surname> <given-names>G</given-names></name><name><surname>Troester</surname> <given-names>MA</given-names></name><name><surname>Tse</surname> <given-names>CK</given-names></name><name><surname>Edmiston</surname> <given-names>S</given-names></name><name><surname>Deming</surname> <given-names>SL</given-names></name><name><surname>Geradts</surname> <given-names>J</given-names></name><name><surname>Cheang</surname> <given-names>MC</given-names></name><name><surname>Nielsen</surname> <given-names>TO</given-names></name><name><surname>Moorman</surname> <given-names>PG</given-names></name><name><surname>Earp</surname> <given-names>HS</given-names></name><name><surname>Millikan</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Race, breast Cancer subtypes, and survival in the carolina breast Cancer study</article-title><source>Jama</source><volume>295</volume><fpage>2492</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1001/jama.295.21.2492</pub-id><pub-id pub-id-type="pmid">16757721</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname> <given-names>LA</given-names></name><name><surname>Berry</surname> <given-names>DA</given-names></name><name><surname>Cirrincione</surname> <given-names>CT</given-names></name><name><surname>Barry</surname> <given-names>WT</given-names></name><name><surname>Pitcher</surname> <given-names>BN</given-names></name><name><surname>Harris</surname> <given-names>LN</given-names></name><name><surname>Ollila</surname> <given-names>DW</given-names></name><name><surname>Krop</surname> <given-names>IE</given-names></name><name><surname>Henry</surname> <given-names>NL</given-names></name><name><surname>Weckstein</surname> <given-names>DJ</given-names></name><name><surname>Anders</surname> <given-names>CK</given-names></name><name><surname>Singh</surname> <given-names>B</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Iglesia</surname> <given-names>M</given-names></name><name><surname>Cheang</surname> <given-names>MC</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Winer</surname> <given-names>EP</given-names></name><name><surname>Hudis</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>542</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.62.1268</pub-id><pub-id pub-id-type="pmid">26527775</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname> <given-names>K</given-names></name><name><surname>DeVries</surname> <given-names>S</given-names></name><name><surname>Fridlyand</surname> <given-names>J</given-names></name><name><surname>Spellman</surname> <given-names>PT</given-names></name><name><surname>Roydasgupta</surname> <given-names>R</given-names></name><name><surname>Kuo</surname> <given-names>WL</given-names></name><name><surname>Lapuk</surname> <given-names>A</given-names></name><name><surname>Neve</surname> <given-names>RM</given-names></name><name><surname>Qian</surname> <given-names>Z</given-names></name><name><surname>Ryder</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Feiler</surname> <given-names>H</given-names></name><name><surname>Tokuyasu</surname> <given-names>T</given-names></name><name><surname>Kingsley</surname> <given-names>C</given-names></name><name><surname>Dairkee</surname> <given-names>S</given-names></name><name><surname>Meng</surname> <given-names>Z</given-names></name><name><surname>Chew</surname> <given-names>K</given-names></name><name><surname>Pinkel</surname> <given-names>D</given-names></name><name><surname>Jain</surname> <given-names>A</given-names></name><name><surname>Ljung</surname> <given-names>BM</given-names></name><name><surname>Esserman</surname> <given-names>L</given-names></name><name><surname>Albertson</surname> <given-names>DG</given-names></name><name><surname>Waldman</surname> <given-names>FM</given-names></name><name><surname>Gray</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Genomic and transcriptional aberrations linked to breast Cancer pathophysiologies</article-title><source>Cancer Cell</source><volume>10</volume><fpage>529</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.009</pub-id><pub-id pub-id-type="pmid">17157792</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciriello</surname> <given-names>G</given-names></name><name><surname>Gatza</surname> <given-names>ML</given-names></name><name><surname>Beck</surname> <given-names>AH</given-names></name><name><surname>Wilkerson</surname> <given-names>MD</given-names></name><name><surname>Rhie</surname> <given-names>SK</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>McLellan</surname> <given-names>M</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Bowlby</surname> <given-names>R</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Hayat</surname> <given-names>S</given-names></name><name><surname>Fieldhouse</surname> <given-names>R</given-names></name><name><surname>Lester</surname> <given-names>SC</given-names></name><name><surname>Tse</surname> <given-names>GM</given-names></name><name><surname>Factor</surname> <given-names>RE</given-names></name><name><surname>Collins</surname> <given-names>LC</given-names></name><name><surname>Allison</surname> <given-names>KH</given-names></name><name><surname>Chen</surname> <given-names>YY</given-names></name><name><surname>Jensen</surname> <given-names>K</given-names></name><name><surname>Johnson</surname> <given-names>NB</given-names></name><name><surname>Oesterreich</surname> <given-names>S</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Robertson</surname> <given-names>G</given-names></name><name><surname>Benz</surname> <given-names>C</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>King</surname> <given-names>TA</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><collab>TCGA Research Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Comprehensive molecular portraits of invasive lobular breast Cancer</article-title><source>Cell</source><volume>163</volume><fpage>506</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.09.033</pub-id><pub-id pub-id-type="pmid">26451490</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>TR</given-names></name><name><surname>Rumney</surname> <given-names>RMH</given-names></name><name><surname>Schoof</surname> <given-names>EM</given-names></name><name><surname>Perryman</surname> <given-names>L</given-names></name><name><surname>Høye</surname> <given-names>AM</given-names></name><name><surname>Agrawal</surname> <given-names>A</given-names></name><name><surname>Bird</surname> <given-names>D</given-names></name><name><surname>Latif</surname> <given-names>NA</given-names></name><name><surname>Forrest</surname> <given-names>H</given-names></name><name><surname>Evans</surname> <given-names>HR</given-names></name><name><surname>Huggins</surname> <given-names>ID</given-names></name><name><surname>Lang</surname> <given-names>G</given-names></name><name><surname>Linding</surname> <given-names>R</given-names></name><name><surname>Gartland</surname> <given-names>A</given-names></name><name><surname>Erler</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The hypoxic Cancer secretome induces pre-metastatic bone lesions through lysyl oxidase</article-title><source>Nature</source><volume>522</volume><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature14492</pub-id><pub-id pub-id-type="pmid">26017313</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname> <given-names>C</given-names></name><name><surname>Shah</surname> <given-names>SP</given-names></name><name><surname>Chin</surname> <given-names>S-F</given-names></name><name><surname>Turashvili</surname> <given-names>G</given-names></name><name><surname>Rueda</surname> <given-names>OM</given-names></name><name><surname>Dunning</surname> <given-names>MJ</given-names></name><name><surname>Speed</surname> <given-names>D</given-names></name><name><surname>Lynch</surname> <given-names>AG</given-names></name><name><surname>Samarajiwa</surname> <given-names>S</given-names></name><name><surname>Yuan</surname> <given-names>Y</given-names></name><name><surname>Gräf</surname> <given-names>S</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Haffari</surname> <given-names>G</given-names></name><name><surname>Bashashati</surname> <given-names>A</given-names></name><name><surname>Russell</surname> <given-names>R</given-names></name><name><surname>McKinney</surname> <given-names>S</given-names></name><name><surname>Langerød</surname> <given-names>A</given-names></name><name><surname>Green</surname> <given-names>A</given-names></name><name><surname>Provenzano</surname> <given-names>E</given-names></name><name><surname>Wishart</surname> <given-names>G</given-names></name><name><surname>Pinder</surname> <given-names>S</given-names></name><name><surname>Watson</surname> <given-names>P</given-names></name><name><surname>Markowetz</surname> <given-names>F</given-names></name><name><surname>Murphy</surname> <given-names>L</given-names></name><name><surname>Ellis</surname> <given-names>I</given-names></name><name><surname>Purushotham</surname> <given-names>A</given-names></name><name><surname>Børresen-Dale</surname> <given-names>A-L</given-names></name><name><surname>Brenton</surname> <given-names>JD</given-names></name><name><surname>Tavaré</surname> <given-names>S</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Aparicio</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title><source>Nature</source><volume>486</volume><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1038/nature10983</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname> <given-names>SJ</given-names></name><name><surname>Rueda</surname> <given-names>OM</given-names></name><name><surname>Aparicio</surname> <given-names>S</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A new genome-driven integrated classification of breast Cancer and its implications</article-title><source>The EMBO Journal</source><volume>32</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.19</pub-id><pub-id pub-id-type="pmid">23395906</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruin</surname> <given-names>EC</given-names></name><name><surname>McGranahan</surname> <given-names>N</given-names></name><name><surname>Mitter</surname> <given-names>R</given-names></name><name><surname>Salm</surname> <given-names>M</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Yates</surname> <given-names>L</given-names></name><name><surname>Jamal-Hanjani</surname> <given-names>M</given-names></name><name><surname>Shafi</surname> <given-names>S</given-names></name><name><surname>Murugaesu</surname> <given-names>N</given-names></name><name><surname>Rowan</surname> <given-names>AJ</given-names></name><name><surname>Grönroos</surname> <given-names>E</given-names></name><name><surname>Muhammad</surname> <given-names>MA</given-names></name><name><surname>Horswell</surname> <given-names>S</given-names></name><name><surname>Gerlinger</surname> <given-names>M</given-names></name><name><surname>Varela</surname> <given-names>I</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Marshall</surname> <given-names>J</given-names></name><name><surname>Voet</surname> <given-names>T</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Rassl</surname> <given-names>DM</given-names></name><name><surname>Rintoul</surname> <given-names>RC</given-names></name><name><surname>Janes</surname> <given-names>SM</given-names></name><name><surname>Lee</surname> <given-names>SM</given-names></name><name><surname>Forster</surname> <given-names>M</given-names></name><name><surname>Ahmad</surname> <given-names>T</given-names></name><name><surname>Lawrence</surname> <given-names>D</given-names></name><name><surname>Falzon</surname> <given-names>M</given-names></name><name><surname>Capitanio</surname> <given-names>A</given-names></name><name><surname>Harkins</surname> <given-names>TT</given-names></name><name><surname>Lee</surname> <given-names>CC</given-names></name><name><surname>Tom</surname> <given-names>W</given-names></name><name><surname>Teefe</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>SC</given-names></name><name><surname>Begum</surname> <given-names>S</given-names></name><name><surname>Rabinowitz</surname> <given-names>A</given-names></name><name><surname>Phillimore</surname> <given-names>B</given-names></name><name><surname>Spencer-Dene</surname> <given-names>B</given-names></name><name><surname>Stamp</surname> <given-names>G</given-names></name><name><surname>Szallasi</surname> <given-names>Z</given-names></name><name><surname>Matthews</surname> <given-names>N</given-names></name><name><surname>Stewart</surname> <given-names>A</given-names></name><name><surname>Campbell</surname> <given-names>P</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Spatial and temporal diversity in genomic instability processes defines lung Cancer evolution</article-title><source>Science</source><volume>346</volume><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1126/science.1253462</pub-id><pub-id pub-id-type="pmid">25301630</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demeulemeester</surname> <given-names>J</given-names></name><name><surname>Kumar</surname> <given-names>P</given-names></name><name><surname>Møller</surname> <given-names>EK</given-names></name><name><surname>Nord</surname> <given-names>S</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Peterson</surname> <given-names>A</given-names></name><name><surname>Mathiesen</surname> <given-names>RR</given-names></name><name><surname>Fjelldal</surname> <given-names>R</given-names></name><name><surname>Zamani Esteki</surname> <given-names>M</given-names></name><name><surname>Theunis</surname> <given-names>K</given-names></name><name><surname>Fernandez Gallardo</surname> <given-names>E</given-names></name><name><surname>Grundstad</surname> <given-names>AJ</given-names></name><name><surname>Borgen</surname> <given-names>E</given-names></name><name><surname>Baumbusch</surname> <given-names>LO</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>White</surname> <given-names>KP</given-names></name><name><surname>Kristensen</surname> <given-names>VN</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Voet</surname> <given-names>T</given-names></name><name><surname>Naume</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tracing the origin of disseminated tumor cells in breast Cancer using single-cell sequencing</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>250</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-1109-7</pub-id><pub-id pub-id-type="pmid">27931250</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname> <given-names>SS</given-names></name><name><surname>Kester</surname> <given-names>L</given-names></name><name><surname>Spanjaard</surname> <given-names>B</given-names></name><name><surname>Bienko</surname> <given-names>M</given-names></name><name><surname>van Oudenaarden</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrated genome and transcriptome sequencing of the same cell</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/nbt.3129</pub-id><pub-id pub-id-type="pmid">25599178</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eirew</surname> <given-names>P</given-names></name><name><surname>Steif</surname> <given-names>A</given-names></name><name><surname>Khattra</surname> <given-names>J</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Yap</surname> <given-names>D</given-names></name><name><surname>Farahani</surname> <given-names>H</given-names></name><name><surname>Gelmon</surname> <given-names>K</given-names></name><name><surname>Chia</surname> <given-names>S</given-names></name><name><surname>Mar</surname> <given-names>C</given-names></name><name><surname>Wan</surname> <given-names>A</given-names></name><name><surname>Laks</surname> <given-names>E</given-names></name><name><surname>Biele</surname> <given-names>J</given-names></name><name><surname>Shumansky</surname> <given-names>K</given-names></name><name><surname>Rosner</surname> <given-names>J</given-names></name><name><surname>McPherson</surname> <given-names>A</given-names></name><name><surname>Nielsen</surname> <given-names>C</given-names></name><name><surname>Roth</surname> <given-names>AJ</given-names></name><name><surname>Lefebvre</surname> <given-names>C</given-names></name><name><surname>Bashashati</surname> <given-names>A</given-names></name><name><surname>de Souza</surname> <given-names>C</given-names></name><name><surname>Siu</surname> <given-names>C</given-names></name><name><surname>Aniba</surname> <given-names>R</given-names></name><name><surname>Brimhall</surname> <given-names>J</given-names></name><name><surname>Oloumi</surname> <given-names>A</given-names></name><name><surname>Osako</surname> <given-names>T</given-names></name><name><surname>Bruna</surname> <given-names>A</given-names></name><name><surname>Sandoval</surname> <given-names>JL</given-names></name><name><surname>Algara</surname> <given-names>T</given-names></name><name><surname>Greenwood</surname> <given-names>W</given-names></name><name><surname>Leung</surname> <given-names>K</given-names></name><name><surname>Cheng</surname> <given-names>H</given-names></name><name><surname>Xue</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Lin</surname> <given-names>D</given-names></name><name><surname>Mungall</surname> <given-names>AJ</given-names></name><name><surname>Moore</surname> <given-names>R</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Lorette</surname> <given-names>J</given-names></name><name><surname>Nguyen</surname> <given-names>L</given-names></name><name><surname>Huntsman</surname> <given-names>D</given-names></name><name><surname>Eaves</surname> <given-names>CJ</given-names></name><name><surname>Hansen</surname> <given-names>C</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Shah</surname> <given-names>SP</given-names></name><name><surname>Aparicio</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dynamics of genomic clones in breast Cancer patient xenografts at single-cell resolution</article-title><source>Nature</source><volume>518</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nature13952</pub-id><pub-id pub-id-type="pmid">25470049</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname> <given-names>MJ</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Shen</surname> <given-names>D</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Suman</surname> <given-names>VJ</given-names></name><name><surname>Wallis</surname> <given-names>JW</given-names></name><name><surname>Van Tine</surname> <given-names>BA</given-names></name><name><surname>Hoog</surname> <given-names>J</given-names></name><name><surname>Goiffon</surname> <given-names>RJ</given-names></name><name><surname>Goldstein</surname> <given-names>TC</given-names></name><name><surname>Ng</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Crowder</surname> <given-names>R</given-names></name><name><surname>Snider</surname> <given-names>J</given-names></name><name><surname>Ballman</surname> <given-names>K</given-names></name><name><surname>Weber</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Koboldt</surname> <given-names>DC</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Schierding</surname> <given-names>WS</given-names></name><name><surname>McMichael</surname> <given-names>JF</given-names></name><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Harris</surname> <given-names>CC</given-names></name><name><surname>McLellan</surname> <given-names>MD</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>DeSchryver</surname> <given-names>K</given-names></name><name><surname>Allred</surname> <given-names>DC</given-names></name><name><surname>Esserman</surname> <given-names>L</given-names></name><name><surname>Unzeitig</surname> <given-names>G</given-names></name><name><surname>Margenthaler</surname> <given-names>J</given-names></name><name><surname>Babiera</surname> <given-names>GV</given-names></name><name><surname>Marcom</surname> <given-names>PK</given-names></name><name><surname>Guenther</surname> <given-names>JM</given-names></name><name><surname>Leitch</surname> <given-names>M</given-names></name><name><surname>Hunt</surname> <given-names>K</given-names></name><name><surname>Olson</surname> <given-names>J</given-names></name><name><surname>Tao</surname> <given-names>Y</given-names></name><name><surname>Maher</surname> <given-names>CA</given-names></name><name><surname>Fulton</surname> <given-names>LL</given-names></name><name><surname>Fulton</surname> <given-names>RS</given-names></name><name><surname>Harrison</surname> <given-names>M</given-names></name><name><surname>Oberkfell</surname> <given-names>B</given-names></name><name><surname>Du</surname> <given-names>F</given-names></name><name><surname>Demeter</surname> <given-names>R</given-names></name><name><surname>Vickery</surname> <given-names>TL</given-names></name><name><surname>Elhammali</surname> <given-names>A</given-names></name><name><surname>Piwnica-Worms</surname> <given-names>H</given-names></name><name><surname>McDonald</surname> <given-names>S</given-names></name><name><surname>Watson</surname> <given-names>M</given-names></name><name><surname>Dooling</surname> <given-names>DJ</given-names></name><name><surname>Ota</surname> <given-names>D</given-names></name><name><surname>Chang</surname> <given-names>LW</given-names></name><name><surname>Bose</surname> <given-names>R</given-names></name><name><surname>Ley</surname> <given-names>TJ</given-names></name><name><surname>Piwnica-Worms</surname> <given-names>D</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Whole-genome analysis informs breast Cancer response to aromatase inhibition</article-title><source>Nature</source><volume>486</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nature11143</pub-id><pub-id pub-id-type="pmid">22722193</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname> <given-names>JM</given-names></name><name><surname>Zhang</surname> <given-names>CZ</given-names></name><name><surname>Maire</surname> <given-names>CL</given-names></name><name><surname>Jung</surname> <given-names>J</given-names></name><name><surname>Manzo</surname> <given-names>VE</given-names></name><name><surname>Adalsteinsson</surname> <given-names>VA</given-names></name><name><surname>Homer</surname> <given-names>H</given-names></name><name><surname>Haidar</surname> <given-names>S</given-names></name><name><surname>Blumenstiel</surname> <given-names>B</given-names></name><name><surname>Pedamallu</surname> <given-names>CS</given-names></name><name><surname>Ligon</surname> <given-names>AH</given-names></name><name><surname>Love</surname> <given-names>JC</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Ligon</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>956</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0879</pub-id><pub-id pub-id-type="pmid">24893890</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridlyand</surname> <given-names>J</given-names></name><name><surname>Snijders</surname> <given-names>AM</given-names></name><name><surname>Ylstra</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Olshen</surname> <given-names>A</given-names></name><name><surname>Segraves</surname> <given-names>R</given-names></name><name><surname>Dairkee</surname> <given-names>S</given-names></name><name><surname>Tokuyasu</surname> <given-names>T</given-names></name><name><surname>Ljung</surname> <given-names>BM</given-names></name><name><surname>Jain</surname> <given-names>AN</given-names></name><name><surname>McLennan</surname> <given-names>J</given-names></name><name><surname>Ziegler</surname> <given-names>J</given-names></name><name><surname>Chin</surname> <given-names>K</given-names></name><name><surname>Devries</surname> <given-names>S</given-names></name><name><surname>Feiler</surname> <given-names>H</given-names></name><name><surname>Gray</surname> <given-names>JW</given-names></name><name><surname>Waldman</surname> <given-names>F</given-names></name><name><surname>Pinkel</surname> <given-names>D</given-names></name><name><surname>Albertson</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Breast tumor copy number aberration phenotypes and genomic instability</article-title><source>BMC Cancer</source><volume>6</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-6-96</pub-id><pub-id pub-id-type="pmid">16620391</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesan</surname> <given-names>S</given-names></name><name><surname>Silver</surname> <given-names>DP</given-names></name><name><surname>Greenberg</surname> <given-names>RA</given-names></name><name><surname>Avni</surname> <given-names>D</given-names></name><name><surname>Drapkin</surname> <given-names>R</given-names></name><name><surname>Miron</surname> <given-names>A</given-names></name><name><surname>Mok</surname> <given-names>SC</given-names></name><name><surname>Randrianarison</surname> <given-names>V</given-names></name><name><surname>Brodie</surname> <given-names>S</given-names></name><name><surname>Salstrom</surname> <given-names>J</given-names></name><name><surname>Rasmussen</surname> <given-names>TP</given-names></name><name><surname>Klimke</surname> <given-names>A</given-names></name><name><surname>Marrese</surname> <given-names>C</given-names></name><name><surname>Marahrens</surname> <given-names>Y</given-names></name><name><surname>Deng</surname> <given-names>CX</given-names></name><name><surname>Feunteun</surname> <given-names>J</given-names></name><name><surname>Livingston</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>BRCA1 supports XIST RNA concentration on the inactive X chromosome</article-title><source>Cell</source><volume>111</volume><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01052-8</pub-id><pub-id pub-id-type="pmid">12419249</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatza</surname> <given-names>ML</given-names></name><name><surname>Silva</surname> <given-names>GO</given-names></name><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast Cancer</article-title><source>Nature Genetics</source><volume>46</volume><fpage>1051</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1038/ng.3073</pub-id><pub-id pub-id-type="pmid">25151356</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iossifov</surname> <given-names>I</given-names></name><name><surname>Ronemus</surname> <given-names>M</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Hakker</surname> <given-names>I</given-names></name><name><surname>Rosenbaum</surname> <given-names>J</given-names></name><name><surname>Yamrom</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>YH</given-names></name><name><surname>Narzisi</surname> <given-names>G</given-names></name><name><surname>Leotta</surname> <given-names>A</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>Grabowska</surname> <given-names>E</given-names></name><name><surname>Ma</surname> <given-names>B</given-names></name><name><surname>Marks</surname> <given-names>S</given-names></name><name><surname>Rodgers</surname> <given-names>L</given-names></name><name><surname>Stepansky</surname> <given-names>A</given-names></name><name><surname>Troge</surname> <given-names>J</given-names></name><name><surname>Andrews</surname> <given-names>P</given-names></name><name><surname>Bekritsky</surname> <given-names>M</given-names></name><name><surname>Pradhan</surname> <given-names>K</given-names></name><name><surname>Ghiban</surname> <given-names>E</given-names></name><name><surname>Kramer</surname> <given-names>M</given-names></name><name><surname>Parla</surname> <given-names>J</given-names></name><name><surname>Demeter</surname> <given-names>R</given-names></name><name><surname>Fulton</surname> <given-names>LL</given-names></name><name><surname>Fulton</surname> <given-names>RS</given-names></name><name><surname>Magrini</surname> <given-names>VJ</given-names></name><name><surname>Ye</surname> <given-names>K</given-names></name><name><surname>Darnell</surname> <given-names>JC</given-names></name><name><surname>Darnell</surname> <given-names>RB</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Schatz</surname> <given-names>MC</given-names></name><name><surname>McCombie</surname> <given-names>WR</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>De novo gene disruptions in children on the autistic spectrum</article-title><source>Neuron</source><volume>74</volume><fpage>285</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.04.009</pub-id><pub-id pub-id-type="pmid">22542183</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>W</given-names></name><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Wan</surname> <given-names>M</given-names></name><name><surname>Cui</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Ren</surname> <given-names>G</given-names></name><name><surname>Ni</surname> <given-names>B</given-names></name><name><surname>Sklar</surname> <given-names>J</given-names></name><name><surname>Przytycka</surname> <given-names>TM</given-names></name><name><surname>Childs</surname> <given-names>R</given-names></name><name><surname>Levens</surname> <given-names>D</given-names></name><name><surname>Zhao</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples</article-title><source>Nature</source><volume>528</volume><fpage>142</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/nature15740</pub-id><pub-id pub-id-type="pmid">26605532</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laks</surname> <given-names>E</given-names></name><name><surname>McPherson</surname> <given-names>A</given-names></name><name><surname>Zahn</surname> <given-names>H</given-names></name><name><surname>Lai</surname> <given-names>D</given-names></name><name><surname>Steif</surname> <given-names>A</given-names></name><name><surname>Brimhall</surname> <given-names>J</given-names></name><name><surname>Biele</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Masud</surname> <given-names>T</given-names></name><name><surname>Ting</surname> <given-names>J</given-names></name><name><surname>Grewal</surname> <given-names>D</given-names></name><name><surname>Nielsen</surname> <given-names>C</given-names></name><name><surname>Leung</surname> <given-names>S</given-names></name><name><surname>Bojilova</surname> <given-names>V</given-names></name><name><surname>Smith</surname> <given-names>M</given-names></name><name><surname>Golovko</surname> <given-names>O</given-names></name><name><surname>Poon</surname> <given-names>S</given-names></name><name><surname>Eirew</surname> <given-names>P</given-names></name><name><surname>Kabeer</surname> <given-names>F</given-names></name><name><surname>Ruiz de Algara</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>SR</given-names></name><name><surname>Taghiyar</surname> <given-names>MJ</given-names></name><name><surname>Huebner</surname> <given-names>C</given-names></name><name><surname>Ngo</surname> <given-names>J</given-names></name><name><surname>Chan</surname> <given-names>T</given-names></name><name><surname>Vatrt-Watts</surname> <given-names>S</given-names></name><name><surname>Walters</surname> <given-names>P</given-names></name><name><surname>Abrar</surname> <given-names>N</given-names></name><name><surname>Chan</surname> <given-names>S</given-names></name><name><surname>Wiens</surname> <given-names>M</given-names></name><name><surname>Martin</surname> <given-names>L</given-names></name><name><surname>Scott</surname> <given-names>RW</given-names></name><name><surname>Underhill</surname> <given-names>TM</given-names></name><name><surname>Chavez</surname> <given-names>E</given-names></name><name><surname>Steidl</surname> <given-names>C</given-names></name><name><surname>Da Costa</surname> <given-names>D</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Coope</surname> <given-names>RJN</given-names></name><name><surname>Corbett</surname> <given-names>R</given-names></name><name><surname>Pleasance</surname> <given-names>S</given-names></name><name><surname>Moore</surname> <given-names>R</given-names></name><name><surname>Mungall</surname> <given-names>AJ</given-names></name><name><surname>Mar</surname> <given-names>C</given-names></name><name><surname>Cafferty</surname> <given-names>F</given-names></name><name><surname>Gelmon</surname> <given-names>K</given-names></name><name><surname>Chia</surname> <given-names>S</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Hansen</surname> <given-names>C</given-names></name><name><surname>Shah</surname> <given-names>SP</given-names></name><name><surname>Aparicio</surname> <given-names>S</given-names></name><collab>CRUK IMAXT Grand Challenge Team</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Clonal decomposition and DNA replication states defined by scaled Single-Cell genome sequencing</article-title><source>Cell</source><volume>179</volume><fpage>1207</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.10.026</pub-id><pub-id pub-id-type="pmid">31730858</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>Park</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Alexander</surname> <given-names>J</given-names></name><name><surname>Moffitt</surname> <given-names>A</given-names></name><name><surname>Ranade</surname> <given-names>N</given-names></name><name><surname>Danyko</surname> <given-names>C</given-names></name><name><surname>Gegenhuber</surname> <given-names>B</given-names></name><name><surname>Fischer</surname> <given-names>S</given-names></name><name><surname>Robinson</surname> <given-names>BD</given-names></name><name><surname>Lepor</surname> <given-names>H</given-names></name><name><surname>Tollkuhn</surname> <given-names>J</given-names></name><name><surname>Gillis</surname> <given-names>J</given-names></name><name><surname>Brouzes</surname> <given-names>E</given-names></name><name><surname>Krasnitz</surname> <given-names>A</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Copolymerization of single-cell nucleic acids into balls of acrylamide gel</article-title><source>Genome Research</source><volume>30</volume><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1101/gr.253047.119</pub-id><pub-id pub-id-type="pmid">31727682</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>CX</given-names></name><name><surname>Reinert</surname> <given-names>T</given-names></name><name><surname>Chmielewska</surname> <given-names>I</given-names></name><name><surname>Ellis</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mechanisms of aromatase inhibitor resistance</article-title><source>Nature Reviews. Cancer</source><volume>15</volume><fpage>261</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/nrc3920</pub-id><pub-id pub-id-type="pmid">25907219</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macaulay</surname> <given-names>IC</given-names></name><name><surname>Haerty</surname> <given-names>W</given-names></name><name><surname>Kumar</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>YI</given-names></name><name><surname>Hu</surname> <given-names>TX</given-names></name><name><surname>Teng</surname> <given-names>MJ</given-names></name><name><surname>Goolam</surname> <given-names>M</given-names></name><name><surname>Saurat</surname> <given-names>N</given-names></name><name><surname>Coupland</surname> <given-names>P</given-names></name><name><surname>Shirley</surname> <given-names>LM</given-names></name><name><surname>Smith</surname> <given-names>M</given-names></name><name><surname>Van der Aa</surname> <given-names>N</given-names></name><name><surname>Banerjee</surname> <given-names>R</given-names></name><name><surname>Ellis</surname> <given-names>PD</given-names></name><name><surname>Quail</surname> <given-names>MA</given-names></name><name><surname>Swerdlow</surname> <given-names>HP</given-names></name><name><surname>Zernicka-Goetz</surname> <given-names>M</given-names></name><name><surname>Livesey</surname> <given-names>FJ</given-names></name><name><surname>Ponting</surname> <given-names>CP</given-names></name><name><surname>Voet</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>G&amp;T-seq: parallel sequencing of single-cell genomes and transcriptomes</article-title><source>Nature Methods</source><volume>12</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3370</pub-id><pub-id pub-id-type="pmid">25915121</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majewski</surname> <given-names>IJ</given-names></name><name><surname>Nuciforo</surname> <given-names>P</given-names></name><name><surname>Mittempergher</surname> <given-names>L</given-names></name><name><surname>Bosma</surname> <given-names>AJ</given-names></name><name><surname>Eidtmann</surname> <given-names>H</given-names></name><name><surname>Holmes</surname> <given-names>E</given-names></name><name><surname>Sotiriou</surname> <given-names>C</given-names></name><name><surname>Fumagalli</surname> <given-names>D</given-names></name><name><surname>Jimenez</surname> <given-names>J</given-names></name><name><surname>Aura</surname> <given-names>C</given-names></name><name><surname>Prudkin</surname> <given-names>L</given-names></name><name><surname>Díaz-Delgado</surname> <given-names>MC</given-names></name><name><surname>de la Peña</surname> <given-names>L</given-names></name><name><surname>Loi</surname> <given-names>S</given-names></name><name><surname>Ellis</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>de Azambuja</surname> <given-names>E</given-names></name><name><surname>Harbeck</surname> <given-names>N</given-names></name><name><surname>Piccart-Gebhart</surname> <given-names>M</given-names></name><name><surname>Bernards</surname> <given-names>R</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast Cancer</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><fpage>1334</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.55.2158</pub-id><pub-id pub-id-type="pmid">25559818</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martelotto</surname> <given-names>LG</given-names></name><name><surname>Baslan</surname> <given-names>T</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>Geyer</surname> <given-names>FC</given-names></name><name><surname>Burke</surname> <given-names>KA</given-names></name><name><surname>Spraggon</surname> <given-names>L</given-names></name><name><surname>Piscuoglio</surname> <given-names>S</given-names></name><name><surname>Chadalavada</surname> <given-names>K</given-names></name><name><surname>Nanjangud</surname> <given-names>G</given-names></name><name><surname>Ng</surname> <given-names>CK</given-names></name><name><surname>Moody</surname> <given-names>P</given-names></name><name><surname>D'Italia</surname> <given-names>S</given-names></name><name><surname>Rodgers</surname> <given-names>L</given-names></name><name><surname>Cox</surname> <given-names>H</given-names></name><name><surname>da Cruz Paula</surname> <given-names>A</given-names></name><name><surname>Stepansky</surname> <given-names>A</given-names></name><name><surname>Schizas</surname> <given-names>M</given-names></name><name><surname>Wen</surname> <given-names>HY</given-names></name><name><surname>King</surname> <given-names>TA</given-names></name><name><surname>Norton</surname> <given-names>L</given-names></name><name><surname>Weigelt</surname> <given-names>B</given-names></name><name><surname>Hicks</surname> <given-names>JB</given-names></name><name><surname>Reis-Filho</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples</article-title><source>Nature Medicine</source><volume>23</volume><fpage>376</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/nm.4279</pub-id><pub-id pub-id-type="pmid">28165479</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marusyk</surname> <given-names>A</given-names></name><name><surname>Tabassum</surname> <given-names>DP</given-names></name><name><surname>Altrock</surname> <given-names>PM</given-names></name><name><surname>Almendro</surname> <given-names>V</given-names></name><name><surname>Michor</surname> <given-names>F</given-names></name><name><surname>Polyak</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity</article-title><source>Nature</source><volume>514</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature13556</pub-id><pub-id pub-id-type="pmid">25079331</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Gindin</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Griffith</surname> <given-names>OL</given-names></name><name><surname>Griffith</surname> <given-names>M</given-names></name><name><surname>Shen</surname> <given-names>D</given-names></name><name><surname>Hoog</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Larson</surname> <given-names>DE</given-names></name><name><surname>Watson</surname> <given-names>M</given-names></name><name><surname>Davies</surname> <given-names>SR</given-names></name><name><surname>Hunt</surname> <given-names>K</given-names></name><name><surname>Suman</surname> <given-names>VJ</given-names></name><name><surname>Snider</surname> <given-names>J</given-names></name><name><surname>Walsh</surname> <given-names>T</given-names></name><name><surname>Colditz</surname> <given-names>GA</given-names></name><name><surname>DeSchryver</surname> <given-names>K</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>Ellis</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>12498</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms12498</pub-id><pub-id pub-id-type="pmid">27502118</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanda</surname> <given-names>R</given-names></name><name><surname>Chow</surname> <given-names>LQ</given-names></name><name><surname>Dees</surname> <given-names>EC</given-names></name><name><surname>Berger</surname> <given-names>R</given-names></name><name><surname>Gupta</surname> <given-names>S</given-names></name><name><surname>Geva</surname> <given-names>R</given-names></name><name><surname>Pusztai</surname> <given-names>L</given-names></name><name><surname>Pathiraja</surname> <given-names>K</given-names></name><name><surname>Aktan</surname> <given-names>G</given-names></name><name><surname>Cheng</surname> <given-names>JD</given-names></name><name><surname>Karantza</surname> <given-names>V</given-names></name><name><surname>Buisseret</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pembrolizumab in patients with advanced Triple-Negative breast Cancer: phase ib KEYNOTE-012 study</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>2460</fpage><lpage>2467</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.8931</pub-id><pub-id pub-id-type="pmid">27138582</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navin</surname> <given-names>N</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>Troge</surname> <given-names>J</given-names></name><name><surname>Andrews</surname> <given-names>P</given-names></name><name><surname>Rodgers</surname> <given-names>L</given-names></name><name><surname>McIndoo</surname> <given-names>J</given-names></name><name><surname>Cook</surname> <given-names>K</given-names></name><name><surname>Stepansky</surname> <given-names>A</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Esposito</surname> <given-names>D</given-names></name><name><surname>Muthuswamy</surname> <given-names>L</given-names></name><name><surname>Krasnitz</surname> <given-names>A</given-names></name><name><surname>McCombie</surname> <given-names>WR</given-names></name><name><surname>Hicks</surname> <given-names>J</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tumour evolution inferred by single-cell sequencing</article-title><source>Nature</source><volume>472</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/nature09807</pub-id><pub-id pub-id-type="pmid">21399628</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Greenman</surname> <given-names>CD</given-names></name><name><surname>Lau</surname> <given-names>KW</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Marshall</surname> <given-names>J</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Shlien</surname> <given-names>A</given-names></name><name><surname>Cooke</surname> <given-names>SL</given-names></name><name><surname>Hinton</surname> <given-names>J</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Stebbings</surname> <given-names>LA</given-names></name><name><surname>Leroy</surname> <given-names>C</given-names></name><name><surname>Jia</surname> <given-names>M</given-names></name><name><surname>Rance</surname> <given-names>R</given-names></name><name><surname>Mudie</surname> <given-names>LJ</given-names></name><name><surname>Gamble</surname> <given-names>SJ</given-names></name><name><surname>Stephens</surname> <given-names>PJ</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>Tarpey</surname> <given-names>PS</given-names></name><name><surname>Papaemmanuil</surname> <given-names>E</given-names></name><name><surname>Davies</surname> <given-names>HR</given-names></name><name><surname>Varela</surname> <given-names>I</given-names></name><name><surname>McBride</surname> <given-names>DJ</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Leung</surname> <given-names>K</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Jönsson</surname> <given-names>G</given-names></name><name><surname>Mariani</surname> <given-names>O</given-names></name><name><surname>Boyault</surname> <given-names>S</given-names></name><name><surname>Miron</surname> <given-names>P</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Langerød</surname> <given-names>A</given-names></name><name><surname>Aparicio</surname> <given-names>SA</given-names></name><name><surname>Tutt</surname> <given-names>A</given-names></name><name><surname>Sieuwerts</surname> <given-names>AM</given-names></name><name><surname>Borg</surname> <given-names>Å</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name><name><surname>Salomon</surname> <given-names>AV</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><collab>Breast Cancer Working Group of the International Cancer Genome Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>The life history of 21 breast cancers</article-title><source>Cell</source><volume>149</volume><fpage>994</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.04.023</pub-id><pub-id pub-id-type="pmid">22608083</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Staaf</surname> <given-names>J</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Glodzik</surname> <given-names>D</given-names></name><name><surname>Zou</surname> <given-names>X</given-names></name><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Ju</surname> <given-names>YS</given-names></name><name><surname>Smid</surname> <given-names>M</given-names></name><name><surname>Brinkman</surname> <given-names>AB</given-names></name><name><surname>Morganella</surname> <given-names>S</given-names></name><name><surname>Aure</surname> <given-names>MR</given-names></name><name><surname>Lingjærde</surname> <given-names>OC</given-names></name><name><surname>Langerød</surname> <given-names>A</given-names></name><name><surname>Ringnér</surname> <given-names>M</given-names></name><name><surname>Ahn</surname> <given-names>SM</given-names></name><name><surname>Boyault</surname> <given-names>S</given-names></name><name><surname>Brock</surname> <given-names>JE</given-names></name><name><surname>Broeks</surname> <given-names>A</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Desmedt</surname> <given-names>C</given-names></name><name><surname>Dirix</surname> <given-names>L</given-names></name><name><surname>Dronov</surname> <given-names>S</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Foekens</surname> <given-names>JA</given-names></name><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Hooijer</surname> <given-names>GK</given-names></name><name><surname>Jang</surname> <given-names>SJ</given-names></name><name><surname>Jones</surname> <given-names>DR</given-names></name><name><surname>Kim</surname> <given-names>HY</given-names></name><name><surname>King</surname> <given-names>TA</given-names></name><name><surname>Krishnamurthy</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Mustonen</surname> <given-names>V</given-names></name><name><surname>O'Meara</surname> <given-names>S</given-names></name><name><surname>Pauporté</surname> <given-names>I</given-names></name><name><surname>Pivot</surname> <given-names>X</given-names></name><name><surname>Purdie</surname> <given-names>CA</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Ramakrishnan</surname> <given-names>K</given-names></name><name><surname>Rodríguez-González</surname> <given-names>FG</given-names></name><name><surname>Romieu</surname> <given-names>G</given-names></name><name><surname>Sieuwerts</surname> <given-names>AM</given-names></name><name><surname>Simpson</surname> <given-names>PT</given-names></name><name><surname>Shepherd</surname> <given-names>R</given-names></name><name><surname>Stebbings</surname> <given-names>L</given-names></name><name><surname>Stefansson</surname> <given-names>OA</given-names></name><name><surname>Teague</surname> <given-names>J</given-names></name><name><surname>Tommasi</surname> <given-names>S</given-names></name><name><surname>Treilleux</surname> <given-names>I</given-names></name><name><surname>Van den Eynden</surname> <given-names>GG</given-names></name><name><surname>Vermeulen</surname> <given-names>P</given-names></name><name><surname>Vincent-Salomon</surname> <given-names>A</given-names></name><name><surname>Yates</surname> <given-names>L</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>van't Veer</surname> <given-names>L</given-names></name><name><surname>Tutt</surname> <given-names>A</given-names></name><name><surname>Knappskog</surname> <given-names>S</given-names></name><name><surname>Tan</surname> <given-names>BK</given-names></name><name><surname>Jonkers</surname> <given-names>J</given-names></name><name><surname>Borg</surname> <given-names>Å</given-names></name><name><surname>Ueno</surname> <given-names>NT</given-names></name><name><surname>Sotiriou</surname> <given-names>C</given-names></name><name><surname>Viari</surname> <given-names>A</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Span</surname> <given-names>PN</given-names></name><name><surname>Van Laere</surname> <given-names>S</given-names></name><name><surname>Lakhani</surname> <given-names>SR</given-names></name><name><surname>Eyfjord</surname> <given-names>JE</given-names></name><name><surname>Thompson</surname> <given-names>AM</given-names></name><name><surname>Birney</surname> <given-names>E</given-names></name><name><surname>Stunnenberg</surname> <given-names>HG</given-names></name><name><surname>van de Vijver</surname> <given-names>MJ</given-names></name><name><surname>Martens</surname> <given-names>JW</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Kong</surname> <given-names>G</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Landscape of somatic mutations in 560 breast Cancer whole-genome sequences</article-title><source>Nature</source><volume>534</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nature17676</pub-id><pub-id pub-id-type="pmid">27135926</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowinski</surname> <given-names>GP</given-names></name><name><surname>Van Dyke</surname> <given-names>DL</given-names></name><name><surname>Tilley</surname> <given-names>BC</given-names></name><name><surname>Jacobsen</surname> <given-names>G</given-names></name><name><surname>Babu</surname> <given-names>VR</given-names></name><name><surname>Worsham</surname> <given-names>MJ</given-names></name><name><surname>Wilson</surname> <given-names>GN</given-names></name><name><surname>Weiss</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The frequency of aneuploidy in cultured lymphocytes is correlated with age and gender but not with reproductive history</article-title><source>American Journal of Human Genetics</source><volume>46</volume><fpage>1101</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">2339703</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname> <given-names>AE</given-names></name><name><surname>Pereira</surname> <given-names>T</given-names></name><name><surname>Silva</surname> <given-names>GL</given-names></name><name><surname>André</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prognostic relevance of DNA flow cytometry in breast Cancer revisited: the 25-year experience of the portuguese institute of oncology of Lisbon</article-title><source>Oncology Letters</source><volume>13</volume><fpage>2027</fpage><lpage>2033</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.5718</pub-id><pub-id pub-id-type="pmid">28454358</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>JB</given-names></name><name><surname>Huh</surname> <given-names>D</given-names></name><name><surname>Noble</surname> <given-names>LB</given-names></name><name><surname>Tavazoie</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification of molecular determinants of primary and metastatic tumour re-initiation in breast Cancer</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>651</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1038/ncb3148</pub-id><pub-id pub-id-type="pmid">25866923</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueda</surname> <given-names>OM</given-names></name><name><surname>Sammut</surname> <given-names>SJ</given-names></name><name><surname>Seoane</surname> <given-names>JA</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Caswell-Jin</surname> <given-names>JL</given-names></name><name><surname>Callari</surname> <given-names>M</given-names></name><name><surname>Batra</surname> <given-names>R</given-names></name><name><surname>Pereira</surname> <given-names>B</given-names></name><name><surname>Bruna</surname> <given-names>A</given-names></name><name><surname>Ali</surname> <given-names>HR</given-names></name><name><surname>Provenzano</surname> <given-names>E</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Parisien</surname> <given-names>M</given-names></name><name><surname>Gillett</surname> <given-names>C</given-names></name><name><surname>McKinney</surname> <given-names>S</given-names></name><name><surname>Green</surname> <given-names>AR</given-names></name><name><surname>Murphy</surname> <given-names>L</given-names></name><name><surname>Purushotham</surname> <given-names>A</given-names></name><name><surname>Ellis</surname> <given-names>IO</given-names></name><name><surname>Pharoah</surname> <given-names>PD</given-names></name><name><surname>Rueda</surname> <given-names>C</given-names></name><name><surname>Aparicio</surname> <given-names>S</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Curtis</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups</article-title><source>Nature</source><volume>567</volume><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1007-8</pub-id><pub-id pub-id-type="pmid">30867590</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruffell</surname> <given-names>B</given-names></name><name><surname>Au</surname> <given-names>A</given-names></name><name><surname>Rugo</surname> <given-names>HS</given-names></name><name><surname>Esserman</surname> <given-names>LJ</given-names></name><name><surname>Hwang</surname> <given-names>ES</given-names></name><name><surname>Coussens</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Leukocyte composition of human breast Cancer</article-title><source>PNAS</source><volume>109</volume><fpage>2796</fpage><lpage>2801</lpage><pub-id pub-id-type="doi">10.1073/pnas.1104303108</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russnes</surname> <given-names>HG</given-names></name><name><surname>Vollan</surname> <given-names>HKM</given-names></name><name><surname>Lingjærde</surname> <given-names>OC</given-names></name><name><surname>Krasnitz</surname> <given-names>A</given-names></name><name><surname>Lundin</surname> <given-names>P</given-names></name><name><surname>Naume</surname> <given-names>B</given-names></name><name><surname>Sørlie</surname> <given-names>T</given-names></name><name><surname>Borgen</surname> <given-names>E</given-names></name><name><surname>Rye</surname> <given-names>IH</given-names></name><name><surname>Langerød</surname> <given-names>A</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Teschendorff</surname> <given-names>AE</given-names></name><name><surname>Stephens</surname> <given-names>PJ</given-names></name><name><surname>Månér</surname> <given-names>S</given-names></name><name><surname>Schlichting</surname> <given-names>E</given-names></name><name><surname>Baumbusch</surname> <given-names>LO</given-names></name><name><surname>Kåresen</surname> <given-names>R</given-names></name><name><surname>Stratton</surname> <given-names>MP</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Zetterberg</surname> <given-names>A</given-names></name><name><surname>Hicks</surname> <given-names>J</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genomic architecture characterizes tumor progression paths and fate in breast Cancer patients</article-title><source>Science Translational Medicine</source><volume>2</volume><elocation-id>38ra47</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3000611</pub-id><pub-id pub-id-type="pmid">20592421</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>SP</given-names></name><name><surname>Roth</surname> <given-names>A</given-names></name><name><surname>Goya</surname> <given-names>R</given-names></name><name><surname>Oloumi</surname> <given-names>A</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Turashvili</surname> <given-names>G</given-names></name><name><surname>Ding</surname> <given-names>J</given-names></name><name><surname>Tse</surname> <given-names>K</given-names></name><name><surname>Haffari</surname> <given-names>G</given-names></name><name><surname>Bashashati</surname> <given-names>A</given-names></name><name><surname>Prentice</surname> <given-names>LM</given-names></name><name><surname>Khattra</surname> <given-names>J</given-names></name><name><surname>Burleigh</surname> <given-names>A</given-names></name><name><surname>Yap</surname> <given-names>D</given-names></name><name><surname>Bernard</surname> <given-names>V</given-names></name><name><surname>McPherson</surname> <given-names>A</given-names></name><name><surname>Shumansky</surname> <given-names>K</given-names></name><name><surname>Crisan</surname> <given-names>A</given-names></name><name><surname>Giuliany</surname> <given-names>R</given-names></name><name><surname>Heravi-Moussavi</surname> <given-names>A</given-names></name><name><surname>Rosner</surname> <given-names>J</given-names></name><name><surname>Lai</surname> <given-names>D</given-names></name><name><surname>Birol</surname> <given-names>I</given-names></name><name><surname>Varhol</surname> <given-names>R</given-names></name><name><surname>Tam</surname> <given-names>A</given-names></name><name><surname>Dhalla</surname> <given-names>N</given-names></name><name><surname>Zeng</surname> <given-names>T</given-names></name><name><surname>Ma</surname> <given-names>K</given-names></name><name><surname>Chan</surname> <given-names>SK</given-names></name><name><surname>Griffith</surname> <given-names>M</given-names></name><name><surname>Moradian</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>SW</given-names></name><name><surname>Morin</surname> <given-names>GB</given-names></name><name><surname>Watson</surname> <given-names>P</given-names></name><name><surname>Gelmon</surname> <given-names>K</given-names></name><name><surname>Chia</surname> <given-names>S</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Curtis</surname> <given-names>C</given-names></name><name><surname>Rueda</surname> <given-names>OM</given-names></name><name><surname>Pharoah</surname> <given-names>PD</given-names></name><name><surname>Damaraju</surname> <given-names>S</given-names></name><name><surname>Mackey</surname> <given-names>J</given-names></name><name><surname>Hoon</surname> <given-names>K</given-names></name><name><surname>Harkins</surname> <given-names>T</given-names></name><name><surname>Tadigotla</surname> <given-names>V</given-names></name><name><surname>Sigaroudinia</surname> <given-names>M</given-names></name><name><surname>Gascard</surname> <given-names>P</given-names></name><name><surname>Tlsty</surname> <given-names>T</given-names></name><name><surname>Costello</surname> <given-names>JF</given-names></name><name><surname>Meyer</surname> <given-names>IM</given-names></name><name><surname>Eaves</surname> <given-names>CJ</given-names></name><name><surname>Wasserman</surname> <given-names>WW</given-names></name><name><surname>Jones</surname> <given-names>S</given-names></name><name><surname>Huntsman</surname> <given-names>D</given-names></name><name><surname>Hirst</surname> <given-names>M</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Aparicio</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The clonal and mutational evolution spectrum of primary triple-negative breast cancers</article-title><source>Nature</source><volume>486</volume><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/nature10933</pub-id><pub-id pub-id-type="pmid">22495314</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>P</given-names></name><name><surname>Allison</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The future of immune checkpoint therapy</article-title><source>Science</source><volume>348</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.aaa8172</pub-id><pub-id pub-id-type="pmid">25838373</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjöblom</surname> <given-names>T</given-names></name><name><surname>Jones</surname> <given-names>S</given-names></name><name><surname>Wood</surname> <given-names>LD</given-names></name><name><surname>Parsons</surname> <given-names>DW</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Barber</surname> <given-names>TD</given-names></name><name><surname>Mandelker</surname> <given-names>D</given-names></name><name><surname>Leary</surname> <given-names>RJ</given-names></name><name><surname>Ptak</surname> <given-names>J</given-names></name><name><surname>Silliman</surname> <given-names>N</given-names></name><name><surname>Szabo</surname> <given-names>S</given-names></name><name><surname>Buckhaults</surname> <given-names>P</given-names></name><name><surname>Farrell</surname> <given-names>C</given-names></name><name><surname>Meeh</surname> <given-names>P</given-names></name><name><surname>Markowitz</surname> <given-names>SD</given-names></name><name><surname>Willis</surname> <given-names>J</given-names></name><name><surname>Dawson</surname> <given-names>D</given-names></name><name><surname>Willson</surname> <given-names>JK</given-names></name><name><surname>Gazdar</surname> <given-names>AF</given-names></name><name><surname>Hartigan</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Parmigiani</surname> <given-names>G</given-names></name><name><surname>Park</surname> <given-names>BH</given-names></name><name><surname>Bachman</surname> <given-names>KE</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The consensus coding sequences of human breast and colorectal cancers</article-title><source>Science</source><volume>314</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1126/science.1133427</pub-id><pub-id pub-id-type="pmid">16959974</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname> <given-names>MR</given-names></name><name><surname>Pandis</surname> <given-names>N</given-names></name><name><surname>Heim</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cytogenetic clues to breast carcinogenesis</article-title><source>Genes, Chromosomes and Cancer</source><volume>33</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1002/gcc.1206</pub-id><pub-id pub-id-type="pmid">11746982</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toy</surname> <given-names>W</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Won</surname> <given-names>H</given-names></name><name><surname>Green</surname> <given-names>B</given-names></name><name><surname>Sakr</surname> <given-names>RA</given-names></name><name><surname>Will</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Gala</surname> <given-names>K</given-names></name><name><surname>Fanning</surname> <given-names>S</given-names></name><name><surname>King</surname> <given-names>TA</given-names></name><name><surname>Hudis</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Taran</surname> <given-names>T</given-names></name><name><surname>Hortobagyi</surname> <given-names>G</given-names></name><name><surname>Greene</surname> <given-names>G</given-names></name><name><surname>Berger</surname> <given-names>M</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Chandarlapaty</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ESR1 ligand-binding domain mutations in hormone-resistant breast Cancer</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1439</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1038/ng.2822</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname> <given-names>NC</given-names></name><name><surname>Ro</surname> <given-names>J</given-names></name><name><surname>André</surname> <given-names>F</given-names></name><name><surname>Loi</surname> <given-names>S</given-names></name><name><surname>Verma</surname> <given-names>S</given-names></name><name><surname>Iwata</surname> <given-names>H</given-names></name><name><surname>Harbeck</surname> <given-names>N</given-names></name><name><surname>Loibl</surname> <given-names>S</given-names></name><name><surname>Huang Bartlett</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Giorgetti</surname> <given-names>C</given-names></name><name><surname>Randolph</surname> <given-names>S</given-names></name><name><surname>Koehler</surname> <given-names>M</given-names></name><name><surname>Cristofanilli</surname> <given-names>M</given-names></name><collab>PALOMA3 Study Group</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Palbociclib in Hormone-Receptor-Positive advanced breast Cancer</article-title><source>New England Journal of Medicine</source><volume>373</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1505270</pub-id><pub-id pub-id-type="pmid">26030518</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname> <given-names>KM</given-names></name><name><surname>Deshpande</surname> <given-names>V</given-names></name><name><surname>Beyter</surname> <given-names>D</given-names></name><name><surname>Koga</surname> <given-names>T</given-names></name><name><surname>Rusert</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Arden</surname> <given-names>K</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Nathanson</surname> <given-names>DA</given-names></name><name><surname>Kornblum</surname> <given-names>HI</given-names></name><name><surname>Taylor</surname> <given-names>MD</given-names></name><name><surname>Kaushal</surname> <given-names>S</given-names></name><name><surname>Cavenee</surname> <given-names>WK</given-names></name><name><surname>Wechsler-Reya</surname> <given-names>R</given-names></name><name><surname>Furnari</surname> <given-names>FB</given-names></name><name><surname>Vandenberg</surname> <given-names>SR</given-names></name><name><surname>Rao</surname> <given-names>PN</given-names></name><name><surname>Wahl</surname> <given-names>GM</given-names></name><name><surname>Bafna</surname> <given-names>V</given-names></name><name><surname>Mischel</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity</article-title><source>Nature</source><volume>543</volume><fpage>122</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/nature21356</pub-id><pub-id pub-id-type="pmid">28178237</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valiente</surname> <given-names>M</given-names></name><name><surname>Obenauf</surname> <given-names>AC</given-names></name><name><surname>Jin</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>XH</given-names></name><name><surname>Lee</surname> <given-names>DJ</given-names></name><name><surname>Chaft</surname> <given-names>JE</given-names></name><name><surname>Kris</surname> <given-names>MG</given-names></name><name><surname>Huse</surname> <given-names>JT</given-names></name><name><surname>Brogi</surname> <given-names>E</given-names></name><name><surname>Massagué</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Serpins promote Cancer cell survival and vascular co-option in brain metastasis</article-title><source>Cell</source><volume>156</volume><fpage>1002</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.01.040</pub-id><pub-id pub-id-type="pmid">24581498</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadan</surname> <given-names>V</given-names></name><name><surname>Gilmore</surname> <given-names>H</given-names></name><name><surname>Miskimen</surname> <given-names>KL</given-names></name><name><surname>Tuck</surname> <given-names>D</given-names></name><name><surname>Parsai</surname> <given-names>S</given-names></name><name><surname>Awadallah</surname> <given-names>A</given-names></name><name><surname>Krop</surname> <given-names>IE</given-names></name><name><surname>Winer</surname> <given-names>EP</given-names></name><name><surname>Bossuyt</surname> <given-names>V</given-names></name><name><surname>Somlo</surname> <given-names>G</given-names></name><name><surname>Abu-Khalaf</surname> <given-names>MM</given-names></name><name><surname>Fenton</surname> <given-names>MA</given-names></name><name><surname>Sikov</surname> <given-names>W</given-names></name><name><surname>Harris</surname> <given-names>LN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Immune signatures following single dose trastuzumab predict pathologic response to PreoperativeTrastuzumab and chemotherapy in HER2-Positive early breast Cancer</article-title><source>Clinical Cancer Research</source><volume>22</volume><fpage>3249</fpage><lpage>3259</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2021</pub-id><pub-id pub-id-type="pmid">26842237</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagenblast</surname> <given-names>E</given-names></name><name><surname>Soto</surname> <given-names>M</given-names></name><name><surname>Gutiérrez-Ángel</surname> <given-names>S</given-names></name><name><surname>Hartl</surname> <given-names>CA</given-names></name><name><surname>Gable</surname> <given-names>AL</given-names></name><name><surname>Maceli</surname> <given-names>AR</given-names></name><name><surname>Erard</surname> <given-names>N</given-names></name><name><surname>Williams</surname> <given-names>AM</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Dickopf</surname> <given-names>S</given-names></name><name><surname>Harrell</surname> <given-names>JC</given-names></name><name><surname>Smith</surname> <given-names>AD</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Wilkinson</surname> <given-names>JE</given-names></name><name><surname>Hannon</surname> <given-names>GJ</given-names></name><name><surname>Knott</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A model of breast Cancer heterogeneity reveals vascular mimicry as a driver of metastasis</article-title><source>Nature</source><volume>520</volume><fpage>358</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nature14403</pub-id><pub-id pub-id-type="pmid">25855289</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname> <given-names>Y</given-names></name><name><surname>Martelotto</surname> <given-names>L</given-names></name><name><surname>Baslan</surname> <given-names>T</given-names></name><name><surname>Vides</surname> <given-names>A</given-names></name><name><surname>Solomon</surname> <given-names>M</given-names></name><name><surname>Mai</surname> <given-names>TT</given-names></name><name><surname>Chaudhary</surname> <given-names>N</given-names></name><name><surname>Riely</surname> <given-names>GJ</given-names></name><name><surname>Li</surname> <given-names>BT</given-names></name><name><surname>Scott</surname> <given-names>K</given-names></name><name><surname>Cechhi</surname> <given-names>F</given-names></name><name><surname>Stierner</surname> <given-names>U</given-names></name><name><surname>Chadalavada</surname> <given-names>K</given-names></name><name><surname>de Stanchina</surname> <given-names>E</given-names></name><name><surname>Schwartz</surname> <given-names>S</given-names></name><name><surname>Hembrough</surname> <given-names>T</given-names></name><name><surname>Nanjangud</surname> <given-names>G</given-names></name><name><surname>Berger</surname> <given-names>MF</given-names></name><name><surname>Nilsson</surname> <given-names>J</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name><name><surname>Reis-Filho</surname> <given-names>JS</given-names></name><name><surname>Rosen</surname> <given-names>N</given-names></name><name><surname>Lito</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An approach to suppress the evolution of resistance in BRAF<sup>V600E</sup>-mutant cancer</article-title><source>Nature Medicine</source><volume>23</volume><fpage>929</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1038/nm.4369</pub-id><pub-id pub-id-type="pmid">28714990</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname> <given-names>LR</given-names></name><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Knappskog</surname> <given-names>S</given-names></name><name><surname>Desmedt</surname> <given-names>C</given-names></name><name><surname>Gundem</surname> <given-names>G</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Aas</surname> <given-names>T</given-names></name><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Larsimont</surname> <given-names>D</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Ju</surname> <given-names>YS</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Haugland</surname> <given-names>HK</given-names></name><name><surname>Lilleng</surname> <given-names>PK</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Glodzik</surname> <given-names>D</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Hinton</surname> <given-names>J</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Mudie</surname> <given-names>LJ</given-names></name><name><surname>Jiang</surname> <given-names>B</given-names></name><name><surname>Vincent</surname> <given-names>D</given-names></name><name><surname>Greene-Colozzi</surname> <given-names>A</given-names></name><name><surname>Adnet</surname> <given-names>PY</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Maetens</surname> <given-names>M</given-names></name><name><surname>Ignatiadis</surname> <given-names>M</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Sotiriou</surname> <given-names>C</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Lønning</surname> <given-names>PE</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Subclonal diversification of primary breast Cancer revealed by multiregion sequencing</article-title><source>Nature Medicine</source><volume>21</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1038/nm.3886</pub-id><pub-id pub-id-type="pmid">26099045</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Fujimoto</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Song</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Seth</surname> <given-names>S</given-names></name><name><surname>Chow</surname> <given-names>CW</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Gumbs</surname> <given-names>C</given-names></name><name><surname>Gold</surname> <given-names>KA</given-names></name><name><surname>Kalhor</surname> <given-names>N</given-names></name><name><surname>Little</surname> <given-names>L</given-names></name><name><surname>Mahadeshwar</surname> <given-names>H</given-names></name><name><surname>Moran</surname> <given-names>C</given-names></name><name><surname>Protopopov</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Tang</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Ye</surname> <given-names>Y</given-names></name><name><surname>William</surname> <given-names>WN</given-names></name><name><surname>Lee</surname> <given-names>JJ</given-names></name><name><surname>Heymach</surname> <given-names>JV</given-names></name><name><surname>Hong</surname> <given-names>WK</given-names></name><name><surname>Swisher</surname> <given-names>S</given-names></name><name><surname>Wistuba</surname> <given-names>II</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing</article-title><source>Science</source><volume>346</volume><fpage>256</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1126/science.1256930</pub-id><pub-id pub-id-type="pmid">25301631</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.51480.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Valencia</surname><given-names>Alfonso</given-names></name><role>Reviewing Editor</role><aff><institution>Barcelona Supercomputing Center - BSC</institution><country>Spain</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Demeulemeester</surname><given-names>Jonas</given-names> </name><role>Reviewer</role><aff><institution>Crick</institution><country>United Kingdom</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Rico</surname><given-names>Daniel</given-names> </name><role>Reviewer</role><aff><institution>Newcastle University</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The analysis of breast cancers at the level of Copy Number Alterations to asses intra-tumoral genetic heterogeneity at the level of single-cell sequencing is an important advance, especially because the results translate into a number of interesting new biological observations, for example, X-loss in ER- tumors and pseudo-diploid cells, among others.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jeffrey Settleman as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Jonas Demeulemeester (Reviewer #1); Daniel Rico (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>Baslan et al. present an in-depth characterization of intratumor copy number heterogeneity in a cohort of 16 primary breast cancer cases: 4 each of the Luminal A, Luminal B, HER2+ and Basal subtype They also generated bulk RNA-seq and bulk genome sequencing for the same samples. The authors isolate nuclei, sort populations with distinct ploidy using FACS, and perform low-pass whole-genome sequencing on an average 116 cells per tumor. Analyses reveal intriguing patterns of both focal and whole-genome copy number heterogeneity which are likely to have clinical relevance. The previous single-cell genome sequencing study in breast cancer primary tumors only included 2 patients (Navin et al., 2011). Therefore, the new dataset presented is the most comprehensive single cell genome sequencing for breast cancer to date. However, the manuscript was not easy to read as there were many different &quot;short stories&quot;, which may be difficult to follow for a non-specialized audience. Also, some of the analysis were not clear, which could be improved by making the code and the data available.</p><p>Essential revisions:</p><p>1) In the second paragraph of the subsection “CNAs and genetic heterogeneity of stromal, non-cancer cells”, the authors describe their breakpoint analysis. At the resolution provided by low-pass whole-genome sequencing, the inferred breakpoints are rough approximations of the true breakends at best. Indeed, authors describe using a window of 3 genomic bins in the Materials and methods. Vice versa, random noise can lead to distinct segmentation in single cells which share a breakend (e.g. the jumps from CN 1 to 2 for the leukaemic cells in Figure 1D). As such, conclusions such as &quot;indicating unique TCRa recombination events&quot;, &quot;none of the T-cells shared identical breakpoints&quot; and &quot;genetically distinct as judged by the deletion breakpoints at their respective TCRa locus&quot; should be stated considerably more carefully.</p><p>2) Pseudo-diploid cells are identified in the samples and authors conclude they are not precursors to the main tumor clone based on their distinct CNAs. Authors should further assess whether these cells represent early, potential evolutionary dead-end tumor subclones or do indeed stem from normal breast epithelia. To do this, authors could carefully call SNVs on the pooled low-pass sequencing data and subsequently genotype the called variants in the single cells.</p><p>3) &quot;High-throughput sequence data should be uploaded before resubmission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)&quot; The data availability section is not very clear: is it already available, in which case I could not find the related project on SRA (= Short Read Archive, not Short Reach Achieve) nor any link to the data.</p><p>4) The analyses of the data shown on Figure 1D are not sufficiently quantitative. Breakpoints accuracy is inherently limited with shallow coverage sequencing and will correlate with technical aspects, such as number of reads, duplicates, noise in the data, etc. The authors merge breakpoints if in adjacent bins but that these four profiles on Figure 1D visually look different is not enough to persuade readers that biological rather than technical effects are driving the differences. As this is a major claim in the manuscript, the authors are encouraged to make the analyses more quantitative (at least consider the impact of one noise metric related to &quot;depth of coverage&quot; in the comparison, as it could be driving the differences between the batches of single nuclei).</p><p>5) Figure 2B: The more single nuclei were sequenced and included in the analyses, the more likely that some events will be considered subclonal (&gt;=10 nuclei with a different state). Hence, before reaching any conclusions, the authors should explicitly correct the fraction of genome subclonal for this. It looks from other figures that the number of nuclei per cancer sample can vary quite substantially thus potentially influencing the subclonal fraction. As a quick check, an easy way to correct for the number of nuclei analyzed would be for each patient, to downsample to the number of nuclei in the patient with the lowest number.</p><p>6) Figure 5A same remark as Figure 2B applies.</p><p>7) It would be useful to also have the processed data available. I could not see if it is actually included in the SRA BioProject (I guess the accession ID is not yet publicly available) but it would be good to have the patient metadata, the gene expression data, CNA calls of both the bulk and the single-cell samples in supplementary data files and/or in a relevant repository for direct download. As gene expression levels and CNA calls do not contain sequence information, these data should be made available without any restrictions.</p><p>8) The results of different interesting analyses are presented to illustrate the usefulness of the data. However, I had the impression that there were several inconclusive stories: the loss of chromosome X, for example, in connection with BRCA1 and X inactivation is intriguing but it is not further investigated. The authors may want to choose if they want to further invest in making the resource data available for different types of users or choose one of the observations (there are up to nine different conclusions in the Discussion!) to extend further for a more solid and complete &quot;Research Article&quot;.</p><p>9) Some strong claims are made regarding the association with biological subtypes and patient stratification. For example, the sub-clonality of each tumor is precisely calculated with hundreds of cells per tumor, but at the end of the day there are only 16 patients, just four per sub-group based on gene expression. Indeed, there are some statistical tests that yielded small p-values (e.g. Figures 3C and 5A) but it is unclear what where the unit of analysis – is the patient the unit of analysis or the cell? The inclusion of the R code used, together with the data, would make the interpretation of these results clearer.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for submitting your article &quot;Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jeffrey Settleman as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Daniel Rico (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>The revised version of the in-depth characterisation of breast cancer cases at the level of copy number heterogeneity at the cell level builds an interesting data set, represents an advanced use of the technology and provides information of potential clinical relevance.</p><p>Summary:</p><p>The revised version of the manuscript has essentially addressed all the key points (i.e. accuracy and level of resolution of the data, cell of origin and linages, and clarification of the narrative and conclusions) but the issues with data and software accessibility have only been partially addressed.</p><p>Essential revisions:</p><p>For the publication of this article, like for any other one, it is essential that the research community has the ability to the reproduce the reported results. In this case, the metadata associated with the processed data in the supplementary file is missing and the software code to reproduce the various analyses presented is not available. These are significant issues that have to be corrected.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.51480.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Summary:</p><p>Baslan et al. present an in-depth characterization of intratumor copy number heterogeneity in a cohort of 16 primary breast cancer cases: 4 each of the Luminal A, Luminal B, HER2+ and Basal subtype They also generated bulk RNA-seq and bulk genome sequencing for the same samples. The authors isolate nuclei, sort populations with distinct ploidy using FACS, and perform low-pass whole-genome sequencing on an average 116 cells per tumor. Analyses reveal intriguing patterns of both focal and whole-genome copy number heterogeneity which are likely to have clinical relevance. The previous single-cell genome sequencing study in breast cancer primary tumors only included 2 patients (Navin et al., 2011). Therefore, the new dataset presented is the most comprehensive single cell genome sequencing for breast cancer to date. However, the manuscript was not easy to read as there were many different &quot;short stories&quot;, which may be difficult to follow for a non-specialized audience. Also, some of the analysis were not clear, which could be improved by making the code and the data available.</p></disp-quote><p>We thank the reviewers for their positive comments and constructive critique of our work. Below we address the requested Essential revisions.</p><p>Regarding the above comment of “the manuscript was not easy to read”: we find this perplexing as many colleagues read the work and did not communicate any sort of illegibility pertaining to the text.</p><p>Structuring the manuscript in the form of “short stories” was done purposely (and for the benefit of a non-specialized audience) because of the number and diversity of intriguing observations that we noted from the analyses.</p><p>Regardless, where we thought it might be off benefit, we have edited certain portions of the text. We hope this makes the text easier to read.</p><p>Lastly, we have addressed the unclear analyses referenced above as well as in the Essential Revisions and made all the data publicly available for anyone to download and analyze (the vast majority of the code used in the communicated manuscript is described in our previous referenced works and can be used to reproduce the data). In addition, we are providing all processed single-cell CNA calls for all single-cancer cells analyzed in this study. These are now provided as supplementary data.</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) In the second paragraph of the subsection “CNAs and genetic heterogeneity of stromal, non-cancer cells”, the authors describe their breakpoint analysis. At the resolution provided by low-pass whole-genome sequencing, the inferred breakpoints are rough approximations of the true breakends at best. Indeed, authors describe using a window of 3 genomic bins in the Materials and methods. Vice versa, random noise can lead to distinct segmentation in single cells which share a breakend (e.g. the jumps from CN 1 to 2 for the leukaemic cells in Figure 1D). As such, conclusions such as &quot;indicating unique TCRa recombination events&quot;, &quot;none of the T-cells shared identical breakpoints&quot; and &quot;genetically distinct as judged by the deletion breakpoints at their respective TCRa locus&quot; should be stated considerably more carefully.</p></disp-quote><p>Points (1) and (4) of Essential revisions critique the same point: TCR breakpoints and clonal lineage relationship.</p><p>Both points are thus collectively addressed here.</p><p>We agree with the reviewers that the listed statements above are factually correct:</p><p>1) “the inferred breakpoints are rough approximations of the true breakend at best”</p><p>2) “the analyses of the data shown on Figure 1D are not sufficiently quantitative”</p><p>3) “… consider the impact of one noise metric related to “depth of coverage” in the comparison…”</p><p>To address this critique, we have performed the following analyses:</p><p>For single T-cell nuclei with at least 1 million uniquely mapped reads derived from: CD8<sup>+</sup>/CD4<sup>+</sup> purified T-cells, a clonal T-cell leukemia, and T-cells identified in breast tumor tissue (including T-cells exhibiting X-chromosome loss), we:</p><p>1) Uniformly down-sampled uniquely mapped sequencing reads to a coverage of 1 million reads.</p><p>2) Re-segmented the “sequencing-depth normalized” datasets to re-compute the breakpoint positions/boundaries for each single-nuclei.</p><p>3) We then calculated pair-wise distances of the genomic bins that lie within the deletion breakpoints for all single-nuclei of each category.</p><p>Low pair-wise distance values indicate a higher probability that the events are clonal due to underlying genetics/biology and not due to technical artifacts. The T-cell leukemia nuclei all shared identical left and right breakpoints.When performing 1 million iterations of random sampling of breakpoint positions (i.e. bins) for the same number of T-cells found in breast tumor biopsies, we find none of these random samples shared identical breakpoints indicating a p-value of &lt; 10<sup>-6</sup>. This analysis is detailed in the main text, the Materials and methods section, and is illustrated in graphical form in Figure 1—figure supplement 2G.</p><p>We have also modified the language in the main text to communicate our conclusions.</p><p>It is important to stress that our T-cell breakpoint analysis was not intended to imply that all T-cells found in a tumor mass are TCRa unique and do not share a clonal lineage. This most certainly is not the case and has been reported in the literature. The purpose of the analyses was to corroborate the intriguing finding of X-loss enrichment in T-cells found in ER-negative disease compared to ER-positive disease.</p><disp-quote content-type="editor-comment"><p>2) Pseudo-diploid cells are identified in the samples and authors conclude they are not precursors to the main tumor clone based on their distinct CNAs. Authors should further assess whether these cells represent early, potential evolutionary dead-end tumor subclones or do indeed stem from normal breast epithelia. To do this, authors could carefully call SNVs on the pooled low-pass sequencing data and subsequently genotype the called variants in the single cells.</p></disp-quote><p>We agree that the nature of pseudo-diploid cells in interesting and warrants further investigation, particularly using a combination of SNV and CNA genotyping as pointed out by the reviewers.</p><p>Unfortunately, this is not something that is feasible with the datasets we have or the material generated in this study.</p><p>1) We did not perform Whole Exome Sequencing on our tumor biopsies to allow precise genotyping of somatic SNVs in our tumor samples (nor can we now perform the experiment for a multitude of reasons).</p><p>2) The depth at which we performed sequencing of single-nuclei (~ 2 million reads per nuclei), even when pooling clonal cancer nuclei, let alone pseudo-diploid nuclei, is not sufficient to allow confident, de-novo calling of somatic SNVs.</p><p>3) Even if we attempted to re-sequence normal, pseudo-diploid, and cancer nuclei to higher coverages, the analysis of the data will still be extremely challenging, particularly for rare events such as pseudo-diploid cells, because the WGA method we employed (DOP-PCR) does not provide coverage of the entire genome for each single nuclei WGA DNA material.</p><p>All the factors listed above, and others, unfortunately precludes us from performing the requested assessment.</p><p>However, the question posed is one of the questions an ongoing study aims to address (a study that is an extension of the work described here). In this ongoing study we have factored this specific subject matter and designed our experimental and analytical protocols to address it.</p><disp-quote content-type="editor-comment"><p>3) &quot;High-throughput sequence data should be uploaded before resubmission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)&quot; The data availability section is not very clear: is it already available, in which case I could not find the related project on SRA (= Short Read Archive, not Short Reach Achieve) nor any link to the data.</p></disp-quote><p>We sincerely apologize for this. Our intention was always to make the data publicly available prior to the review of the manuscript. The reason the data was not available (and escaped our knowledge) is because of an apparent corrupted syntax of a subset of the sequencing files that prevented “completion” of the SRA upload and consequently, data release.</p><p>All data has now been verified to be released and publicly available.</p><disp-quote content-type="editor-comment"><p>4) The analyses of the data shown on Figure 1D are not sufficiently quantitative. Breakpoints accuracy is inherently limited with shallow coverage sequencing and will correlate with technical aspects, such as number of reads, duplicates, noise in the data, etc. The authors merge breakpoints if in adjacent bins but that these four profiles on Figure 1D visually look different is not enough to persuade readers that biological rather than technical effects are driving the differences. As this is a major claim in the manuscript, the authors are encouraged to make the analyses more quantitative (at least consider the impact of one noise metric related to &quot;depth of coverage&quot; in the comparison, as it could be driving the differences between the batches of single nuclei).</p></disp-quote><p>This is addressed above. Please see point 1.</p><disp-quote content-type="editor-comment"><p>5) Figure 2B: The more single nuclei were sequenced and included in the analyses, the more likely that some events will be considered subclonal (&gt;=10 nuclei with a different state). Hence, before reaching any conclusions, the authors should explicitly correct the fraction of genome subclonal for this. It looks from other figures that the number of nuclei per cancer sample can vary quite substantially thus potentially influencing the subclonal fraction. As a quick check, an easy way to correct for the number of nuclei analyzed would be for each patient, to downsample to the number of nuclei in the patient with the lowest number.</p></disp-quote><p>We thank the reviewers for bringing this issue up and naturally agree with regards to the influence of the # of single nuclei sequenced and the proportion of the genome found to be sub-clonal. We have done the requested down-sampling analysis above and find no significant differences in the computed fraction of the of the genome found to be sub-clonal for all the tumors with the exception of two (P5 and P58).</p><p>Importantly, when performing Wilcoxon rank order testing for statistical associations with discrete and continuous variables, as done in the original submitted work, the change of order of the tumors does not change the statistical significance of the results (i.e. p-values).</p><p>Thus, given that the original data (i.e. computed sub-clonal values with all single nuclei factored) represents a more accurate measurement per tumor and that the results following down-sampling normalization do not impact our conclusions, we have kept the stats (and figures) as originally reported.</p><disp-quote content-type="editor-comment"><p>6) Figure 5A same remark as Figure 2B applies.</p></disp-quote><p>Please see point 5 above.</p><disp-quote content-type="editor-comment"><p>7) It would be useful to also have the processed data available. I could not see if it is actually included in the SRA BioProject (I guess the accession ID is not yet publicly available) but it would be good to have the patient metadata, the gene expression data, CNA calls of both the bulk and the single-cell samples in supplementary data files and/or in a relevant repository for direct download. As gene expression levels and CNA calls do not contain sequence information, these data should be made available without any restrictions.</p></disp-quote><p>The critique here is similar to the critique outlined in point 3. In addition, in our revised work we are including all processed, integer copy number calls for all the cancer cells found in the tumor samples analyzed at a bin resolution of 600kb (i.e. diving the genome into 5,000 bins – 5k).</p><disp-quote content-type="editor-comment"><p>8) The results of different interesting analyses are presented to illustrate the usefulness of the data. However, I had the impression that there were several inconclusive stories: the loss of chromosome X, for example, in connection with BRCA1 and X inactivation is intriguing but it is not further investigated. The authors may want to choose if they want to further invest in making the resource data available for different types of users or choose one of the observations (there are up to nine different conclusions in the Discussion!) to extend further for a more solid and complete &quot;Research Article&quot;.</p></disp-quote><p>Please see above (3 and 7) regarding data release: all data has been publicly released and is available for download. We are also including all processed data from cancer cells as supplementary data. We feel a strength of our study lies in communicating the usefulness of single-cell genomics in furthering an understanding of cancer – which is pointed out in the text. This is very important since single-cell genomics in reality has not progressed sufficiently enough in comparison to single-cell transcriptomics (due to many reasons).</p><p>Thus, one of the aims of our manuscript was to communicate the importance of single-cell genomics that would entice the research community to adopt single-cell genomics.</p><p>We feel the importance of single cell genomics was sufficiently communicated in our work by illustrating the panoply of novel genetics observations that where gleaned from the data as a whole rather than focusing on one particular observation.</p><p>Thus, it is our opinion that communicating a plethora of novel findings, and emphasizing the power of single-cell genomics in retrieving those findings, we are communicating a “complete Research Article”.</p><p>Regarding the comment about the interesting link BRCA1 and X-chromosome loss in T-cells: we agree with the reviewer. This is something we hope to further address in ongoing studies (please see point 2 above).</p><disp-quote content-type="editor-comment"><p>9) Some strong claims are made regarding the association with biological subtypes and patient stratification. For example, the sub-clonality of each tumor is precisely calculated with hundreds of cells per tumor, but at the end of the day there are only 16 patients, just four per sub-group based on gene expression. Indeed, there are some statistical tests that yielded small p-values (e.g. Figures 3C and 5A) but it is unclear what where the unit of analysis – is the patient the unit of analysis or the cell? The inclusion of the R code used, together with the data, would make the interpretation of these results clearer.</p></disp-quote><p>We are not entirely certain what is meant by “strong” claims. If by “strong claims” the reviewers mean “exaggeration”, we respectfully disagree.</p><p>To illustrate, regarding the association of CNA heterogeneity with molecular and clinical parameter (i.e. biological subtypes and patient stratification), in the Discussion section we explicitly state “the association of CNA heterogeneity with parameters such as polyploidy and ER- status provides <italic>an indirect association</italic> of heterogeneity with clinical parameters”.</p><p>“Indirect association” cannot be construed as a “strong” claim in our opinion.</p><p>Similarly, we explicitly state “we see <italic>somewhat</italic> of an inverse correlation between tumor size and CNA heterogeneity”. “Somewhat” does not communicate a “strong claim” either.</p><p>We are simply laying out all the observations we have been able to glean from the data in an effort to illustrate:</p><p>1) The magnitude of CNA heterogeneity in breast cancer and hypothesize about its effect on the biology of tumors.</p><p>2) The importance of single-cell genomics in studying cancer.</p><p>Regarding the p-values and the unit of the analysis comment above:</p><p>We believe it is clear that for Figure 3C, the unit is a single-cell since we are describing a single tumor.</p><p>Similarly for Figure 5A, the unit is the patient since we are discussing the tumor cohort.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>For the publication of this article, like for any other one, it is essential that the research community has the ability to the reproduce the reported results. In this case, the metadata associated with the processed data in the supplementary file is missing and the software code to reproduce the various analyses presented is not available. These are significant issues that have to be corrected.</p></disp-quote><p>The metadata on all tumor samples analyzed is now included in the revised version (Figure 1—source data 1). The software code to process the sequencing data (i.e. derive integer copy number state) has been described in detail in the literature and is appropriately cited. The source code for deriving two metrics used in statistical associations: (1) % genome sub-clonal and (2) clonal/subclonal pins/breakpoints, are now included as a supplementary file and a URL, respectively.</p></body></sub-article></article>